In-VIVO t cell engineering for the treatment of autoimmune diseases

The use of a non-integrating AAV vector for in-vivo delivery of CARs in autoimmune diseases addresses logistical and safety issues of adoptive therapies, providing efficient and transient B cell depletion with reduced complexity and cost.

WO2026239383A1PCT designated stage Publication Date: 2026-11-19RAMOT AT TEL AVIV UNIVERSITY LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IL2026/050396
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-12
Filing Date
2026-05-12
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current adoptive T cell therapies for autoimmune diseases are costly, time-consuming, and logistically complex, and face challenges such as graft-versus-host reactions and the need for lymphodepletion, while in-vivo strategies have limitations with genomic integration and transgene expression duration control.

Method used

A non-integrating AAV vector is used to deliver a nucleic acid sequence encoding a heterologous immune cell activating transmembrane protein, such as a CAR, for transient expression in target immune cells, avoiding genome integration and enabling efficient, transient depletion of autoreactive B cells.

Benefits of technology

This approach induces therapeutic immune modulation in autoimmune diseases like SLE, achieving rapid CAR expression and efficient B cell depletion without ex vivo manipulation, reducing disease pathology and anti-DNA antibody levels.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000040_0001_TABLE
    Figure IMGF000040_0001_TABLE
  • Figure IMGF000042_0001_TABLE
    Figure IMGF000042_0001_TABLE
  • Figure IMGF000043_0001_TABLE
    Figure IMGF000043_0001_TABLE
Patent Text Reader

Abstract

In-vivo T cell engineering for the treatment of autoimmune diseases is provided. Accordingly, there is provided a composition comprising an adeno-associated virus vector comprising a nucleic acid sequence encoding a heterologous immune cell activating transmembrane protein, wherein the composition is devoid of a genome integration moiety such that the nucleic acid sequence is transiently expressed in a cell infected with the composition.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] IN-VIVO T CELL ENGINEERING FOR THE TREATMENT OF AUTOIMMUNE DISEASES

[0002] RELATED APPLICATION / S

[0003] This application claims the benefit of priority of US Provisional Patent Application No. 63 / 804,001 filed on May 12, 2025, the contents of which are incorporated herein by reference in their entirety.

[0004] SEQUENCE LISTING STATEMENT

[0005] The XML file, entitled 107194, created on May 11, 2026, comprising 28,672 bytes, submitted concurrently with the filing of this application is incorporated herein by reference.

[0006] FIELD AND BACKGROUND OF THE INVENTION

[0007] The present invention, in some embodiments thereof, relates to in-vivo T cell engineering for the treatment of autoimmune diseases.

[0008] Immunotherapy for autoimmune diseases aims to modulate the immune system to reduce pathological immune responses while preserving essential immune function. Current therapeutic strategies include systemic immunosuppressants, cytokine blockade (e.g., anti-TNF or anti-IL-6 therapies), B cell depletion (such as anti-CD20 antibodies), immune checkpoint modulation, tolerogenic vaccines, antigen- specific nanoparticles, and various T cell-based interventions. Among these, adoptive T cell therapy offers a particularly promising avenue by enabling the precise manipulation of T cells to suppress or modulate autoreactive immune responses that drive disease progression. In this context, T cells can be engineered, for example, to express high-affinity T cell receptors (TCRs) targeting autoantigens presented via MHC molecules, or to express chimeric antigen receptors (CARs) that recognize intact surface proteins in an MHC-independent manner.

[0009] However, despite their promise, adoptive T cell therapies rely on ex- vivo cell processing. This involves isolation, engineering and expansion of T cells in specialized laboratory facilities -an approach that is costly, time-consuming and logistically complex. Further, when employing allogeneic T cells, issues like graft-versus-host and host-versus-graft reactions remain challenges, and the requirement for lymphodepletion or other preconditioning regimens further limit widespread application.

[0010] To address these limitations, in-vivo T cell engineering has emerged as a transformative alternative, aiming to generate therapeutic T cells directly within the patient’s body. One strategy involves AAV-based delivery systems for site-specific gene transfer [see, e.g.,International Patent Application Publication No. WO2023187779; Nyberg WA et al. Immunity, 58(2), 499-512.e7 (2025); Nyberg WA et al. Cell, 186(2): 446-460.el9 (2023)]. Additional approaches under investigation include lentiviral vector-based platforms, such as Sana Biotechnology’s SG299 and Umoja Biopharma’s VivoVec™ system. Other strategies employ lipid nanoparticles (e.g., Capstan Therapeutics) and nanoparticle -based mRNA delivery systems (e.g., BioNTech’s BNT211). These diverse technologies aim to bypass the need for ex vivo cell manipulation, offering a more streamlined and potentially scalable and patient-friendly therapeutic solution.

[0011] Additional Background Art includes:

[0012] Kansal, R. et al. Sci. Transl. Med. 11, (2019);

[0013] Mullard, A. Nat. Rev. Drug Discov. 22, 859-861 (2023);

[0014] Mackensen, A. et al. Nat. Med. 28, 2124-2132 (2022); and

[0015] Muller, F. et al. N. Engl. J. Med. 390, (2024).

[0016] SUMMARY OF THE INVENTION

[0017] According to an aspect of some embodiments of the present invention there is provided a composition comprising an adeno-associated virus (AAV) vector comprising a nucleic acid sequence encoding a heterologous immune cell activating transmembrane protein comprising an extracellular binding domain that binds an antigen expressed by a target immune cell; and a cisacting regulatory element for directing expression of the nucleic acid sequence, wherein the composition is devoid of a genome integration moiety such that the nucleic acid sequence is transiently expressed in a cell infected with the composition.

[0018] According to some embodiments of the invention, the immune cell activating transmembrane protein is a T cell transmembrane protein.

[0019] According to some embodiments of the invention, the immune cell transmembrane protein is selected from the group consisting of a chimeric antigen receptor (CAR), a chimeric autoantibody receptor (CAAR) and a T cell receptor (TCR).

[0020] According to some embodiments of the invention, the immune cell transmembrane protein is a chimeric antigen receptor (CAR).

[0021] According to some embodiments of the invention, the target immune cell is a B cell. According to some embodiments of the invention, the antigen is selected from the group consisting of CD 19, CD20 and IgE receptor.

[0022] According to some embodiments of the invention, the antigen is CD 19.According to some embodiments of the invention, the immune cell transmembrane protein comprises an intracellular domain of CD3zeta and an intracellular domain of a costimulatory molecule.

[0023] According to some embodiments of the invention, the costimulatory molecule is CD28. According to some embodiments of the invention, the AAV vector comprises a T cell targeting moiety.

[0024] According to some embodiments of the invention, the T cell targeting moiety is selected from the group consisting of a Designed Ankyrin Repeat Protein (DARPin), an antibody, a ligand and a peptide mimetic.

[0025] According to some embodiments of the invention, the cis-acting regulatory element comprises a promoter.

[0026] According to some embodiments of the invention, the promoter is a constitutive promoter.

[0027] According to some embodiments of the invention, the promoter is selected from the group consisting of PGK, EFla and MSCV.

[0028] According to some embodiments of the invention, the promoter is a T cell specific promoter.

[0029] According to some embodiments of the invention, the nucleic acid sequence further comprises a polyadenylation signal.

[0030] According to some embodiments of the invention, the vector further encodes an additional heterologous expression product selected from the group consisting of a therapeutic agent, a detectable agent and a safety switch.

[0031] According to an aspect of some embodiments of the present invention there is provided a method of treating an autoimmune disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the composition, thereby treating the autoimmune disease in the subject.

[0032] According to an aspect of some embodiments of the present invention there is provided the composition for use in treating an autoimmune disease in a subject in need thereof.

[0033] According to some embodiments of the invention, the autoimmune disease is selected from the group consisting of systemic lupus erythematosus (SLE), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Myasthenia Gravis (MG), Multiple Sclerosis (MS), Sjogren’s Syndrome (SjD) and Rheumatoid Arthritis (RA).

[0034] According to some embodiments of the invention, the autoimmune disease is systemic lupus erythematosus (SLE).According to some embodiments of the invention, the composition is administered intravenously.

[0035] Unless otherwise defined, all technical and / or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and / or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.

[0036] BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

[0037] Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.

[0038] In the drawings:

[0039] FIGs. 1A-F demonstrate autoreactive B cell depletion following IV administration of an AAV vector coding for a CAR anti-CD19 (denoted in Figures 1A-7 and 9A-11M hereinafter as “scAAV8-CAR anti-CD19”, “scAAV8-CAR”, “AAV8CAR”, “AAV8-CAR”, “AAVCAR” or just “AAV”) into 11 weeks old MRL-lpr mice. Figure 1A shows a schematic representation of the experiment timeline. Figure IB shows representative flow cytometry analysis of peripheral blood B cells (upper panel) and T cells (lower panel) from mice treated with scAAV8-CAR anti-CD19 or with PBS, analyzed at day 8 after scAAV8-CAR injection. Figure 1C shows quantification of Figure IB at different time points. Figure ID shows IgG anti-DNA titers in MRL-lpr mice plasma samples, as evaluate by ELISA. Figure IE shows histological evaluation of kidneys from MRL-lpr mice analyzed for cellularity and morphology by H&E (magnification X10) and PAS (magnification X20) stainings. In the PBS-injected mouse H&E staining: periarterial infiltrations are indicated by yellow arrows; a periglomerular immune response (with a severe loss of the glomerular structure) is indicated by black arrows; severe accumulation of protein in the kidney tubule is indicated by green arrows. In the PBS-injected mouse PAS staining: Severe thickening of the glomerular membrane is indicated by yellow arrows; as wellas an accumulation of protein and loss of glomerular structure indicated in green arrows. In the scAAV8-C AR- injected mouse H&E staining: reduced periarterial inflammatory infiltrations are indicated by a yellow arrow. In the scAAV8-CAR-injected mouse PAS staining: no thickening of the glomerular membrane. Figure IF shows the pathology scores of MRL-lpr kidney sections, determined as described in Materials and Methods. Data points indicate mean+ / - SEM. n=5, * = P<0.05, ** = P<0.005, *** = P<0.0005, NS - not significant for two-way ANOVA (1C), paired t-test (ID), unpaired t-test (IF).

[0040] FIG. 2 demonstrates counts of CD19+CD20+cells (left) and CD3+cells (right) in the spleens of scAAV8-CAR-treated mice versus PBS-treated controls, measured one-week postinjection. Data points indicate mean+ / - SEM. n=4 for PBS, n=5 for AAV, * = P<0.05, ** = P<0.005, *** = P<0.0005, NS - not significant for unpaired t-test.

[0041] FIG. 3 demonstrates counts of CD19+CD20+cells (left) and CD3+cells (right) in the bone marrow of scAAV8-CAR-treated mice versus PBS-treated controls, measured one-week postinjection. Data points indicate mean+ / - SEM. n=4 for PBS group, n=5 for AAV group, * = P<0.05, ** = P<0.005, *** = P<0.0005, NS - not significant for unpaired t-test.

[0042] FIG. 4 demonstrates counts of CD3+cell populations in the peripheral blood of scAAV8-CAR-treated mice versus PBS-treated controls, measured one-week post-injection. Data points indicate mean+ / - SEM. n=5 for PBS, n=4 for AAV, * = P<0.05, ** = P<0.005, *** = P<0.0005, NS - not significant for unpaired t-test.

[0043] FIG. 5 shows spleen length in mice treated with scAAV8-CAR compared to PBS-injected control mice, measured 10-weeks post- injection. Numbers below each spleen denote arbitrary identifiers assigned to individual mice.

[0044] FIG. 6 is a survival curve of MRL-lpr mice following scAAV8-CAR injection (n=7) compared to PBS-injected controls (n=5).

[0045] FIG. 7 demonstrates the in-vivo biodistribution of the injected scAAV8-CAR vectors, as evaluated by qPCR analysis in collected organs 1 week after AAV injection (n=5). BM - Bone Marrow. Each sample was analyzed for both internal control (IgGl heavy chain) and the donor AAV. For quantification of donor AAV copy number per haploid genome, a standard curve was used. Data points indicate mean+ / - SEM.

[0046] FIGs. 8A-B show the AAV vector used in Example 1, containing a polynucleotide encoding an anti-mouse CD 19 CAR payload driven by a PGK promoter, designed for transient expression in infected cells. Figure 8A is a schematic representation of the construct; and Figure 8B shows the sequences, highlighting the elements comprised therein.FIGs. 9A-D demonstrates ex-vivo generation of functional anti-CD19 CAR T cells by transducing murine splenocytes with the AAV8-CAR vector. Figure 9A shows a representative flow cytometry analysis of CAR expression in T cells, assessed by anti-flag staining. Figure 9B is a graph showing the quantification of Figure 9A. Figure 9C shows a representative flow cytometry analysis of the rate of CD19+B cells among lymphocytes. Figure 9D is a graph shown the quantification of Figure 9C. UT - untreated. n=4. Bars indicate mean ± SEM; *P<0.05, **P<0.01, ***P<0.001 by unpaired T test.

[0047] FIGs. 10A-G demonstrate in-vivo generation of CAR-T cells following IV administration of scAAV8-CAR anti-CD19 induces robust B cell aplasia. Figure 10A shows a schematic representation of the experiment timeline in C57BL healthy mice. Figure 10B shows representative flow cytometry analysis of circulating cdl9+B cells in mice treated with scAAV8-CAR anti-CD19 or with HBSS, analyzed at day 7 post treatment. Figure 10C shows quantification of Figure 10B at different time points. Figure 10D shows a representative flow cytometry analysis of circulating CD20+B cells in mice treated with scAAV8-CAR anti-CD19 or with HBSS, analyzed at day 21 post treatment. Figure 10E shows quantification of Figure 10D at different time points. Figure 10F shows a representative flow cytometry analysis of circulating T cells in mice treated with scAAV8-CAR anti-CD19 or with HBSS, analyzed at day 7 post treatment. Figure 10G shows quantification of Figure 10F at different time points. n=5, data points indicate mean ± SEM; *P<0.05, **P<0.01, ***P<0.001, ns, non-significant, two-way ANOVA.

[0048] FIGs. 11A-M demonstrate autoreactive B cell depletion following IV administration of an AAV vector coding for a CAR anti-CD19 into 13 weeks old MRL-lpr mice. Figure 11A shows a schematic representation of the experiment timeline. Figure 11B shows representative flow cytometry analysis of peripheral blood B cells from mice treated with scAAV8-CAR anti-CD19 or with PBS, analyzed at day 21 after scAAV8-CAR injection. Figure 11C shows quantification of Figure 11B at different time points. Figure 11D shows representative flow cytometry analysis of peripheral CD3+CD8+T cells from mice treated with scAAV8-CAR anti-CD19 or with PBS. Figure HE shows quantification of Figure 11D at different time points. n=10 in PBS group, 77=12 in scAAV8 CAR group; Data points indicate mean ± SEM; * = P<0.05, ** = P<0.005, *** = P<0.0005, NS - not significant for two-way ANOVA. Figure 11F shows a representative flow cytometry analysis of CD19+CD20+cells in the bone marrow of mice treated with scAAV8-CAR anti-CD19 or with PBS, analyzed one-week post-injection. Figure 11G is a quantification of Figure 1 IF. Figure 11H shows analysis of CD3+cells in the bone marrow of mice treated with scAAV8-CAR anti-CD19 or with PBS, analyzed one weekpost injection. Figure 111 shows quantification of Figure 11H. n=4 for PBS group, n=5 for AAV group; Data points indicate mean± SEM; * = P<0.05, ** = P<0.005, *** = P<0.0005, NS -not significant for unpaired t-test. Figure 11 J shows a representative analysis and counts of CD3+cell populations (CD44 / CD62L) in the peripheral blood of mice treated with scAAV8-CAR anti-CD19 or with PBS, analyzed one-week post-injection. Figure UK shows a quantification of Figure 11J. n=5 for PBS, n=4 for scAAV8-CAR; Data points indicate mean ± SEM; * = P<0.05, ** = P<0.005, *** = P<0.0005, NS - not significant for unpaired t-test. Figure 11L shows IgG anti-DNA titers in MRL-lpr mice plasma samples, as evaluate by ELISA. Figure 11M demonstrate % proteinuria mice treated with scAAV8-CAR anti-CD19 or with PBS, analyzed 10 weeks post-injection.

[0049] DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION

[0050] The present invention, in some embodiments thereof, relates to in-vivo T cell engineering for the treatment of autoimmune diseases.

[0051] Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.

[0052] Immunotherapy for autoimmune diseases seeks to selectively modulate pathological immune responses while preserving essential immune function. Adoptive T cell therapies, including chimeric antigen receptor (CAR) T cell approaches, have shown significant promise in targeting disease-driving immune cells, particularly in B cell-mediated disorders such as systemic lupus erythematosus (SLE). However, current strategies rely predominantly on ex vivo manipulation of T cells, which is complex, costly and associated with logistical and safety limitations, including those arising from donor selection, cell processing and handling.

[0053] In vivo strategies for generating engineered T cells have been proposed, including viral and non-viral delivery systems. These approaches, however, remain limited by challenges including risks associated with genomic integration or insufficient control over the duration of transgene expression.

[0054] The present inventors have now devised a gene delivery approach based on adeno-associated virus (AAV) vectors configured to express immune cell activating transmembrane proteins, such as chimeric antigen receptors (CARs), in vivo in a manner that is intentionally transient and substantially devoid of genomic integration.As illustrated hereinunder and in the Examples section which follows, the present inventors show that systemic administration of a self-complementary AAV vector encoding an anti-CD19 CAR induces in vivo generation of functional CAR-T cells, resulting in robust yet transient depletion of B cells (Example 1). In a murine model of systemic lupus erythematosus (SLE, MRL-lpr), this transient CAR expression is sufficient to induce therapeutic immune modulation, including depletion of autoreactive B cells, reduction in anti-double-stranded DNA antibody levels and amelioration of disease pathology (Example 1).

[0055] Hence, the present inventors show that transient CAR expression achieved by in vivo delivery of a non-integrating AAV vector is sufficient to induce a therapeutic effect in an autoimmune disease setting. This approach enables rapid onset of CAR expression and efficient functional activity without the need for ex vivo T cell manipulation or lymphodepleting conditioning, and provides a temporally limited period of CAR-T cell activity sufficient to induce modulation of target immune cells, with a duration of expression that is longer than that achieved by mRNA delivery yet limited relative to integrating systems.

[0056] Consequently, specific embodiments of the present teachings suggest non-integrating AAV vectors for in vivo generation of immune-modulating cells.

[0057] Thus, according to an aspect of the present invention, there is provided a composition comprising an adeno-associated virus (AAV) vector comprising a nucleic acid sequence encoding a heterologous immune cell activating transmembrane protein comprising an extracellular binding domain that binds an antigen expressed by a target immune cell; and a cisacting regulatory element for directing expression of said nucleic acid sequence, wherein said composition is devoid of a genome integration moiety such that said nucleic acid sequence is transiently expressed in a cell infected with said composition.

[0058] As used herein, the term “Adeno-associated virus (AAV) vector” refers to a recombinant adeno-associated virus (rAAV) viral particle, or virion, which comprises a proteinaceous capsid encapsidating a heterologous nucleic acid sequence of interest to be expressed in an AAV-infected host cell, the heterologous sequence is flanked by inverted terminal repeats (ITRs) derived from AAV.

[0059] According to some embodiments, the AAV based capsid is derived from a naturally occurring AAV serotype, including but not limited to AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8 or AAV-9, or from engineered or hybrid serotypes such as AAV-DJ or AAV-X7. According to specific embodiments, the capsid is derived from AAV-8. The capsid typically comprises three viral proteins: VP1, VP2, and VP3. In some embodiments, the capsid comprises one or more modified viral proteins containing amino acid substitutions that enhancetransduction efficiency, alter tissue specificity or reduce immunogenicity (e.g., US20220193263).

[0060] The encapsidated nucleic acid sequence is flanked by functional ITRs derived from AAV, which enable replication and packaging of the vector during production. The nucleic acid sequence may be operably linked to one or more transcriptional and regulatory elements that control or enhance its expression, including but not limited to promoter sequences, enhancer elements, polyadenylation signals, selectable markers or tags, reporter genes, and other control sequences known in the art (e.g., WO 93 / 03769), as further described hereinbelow. The AAV vector may be in the form of a single- stranded AAV (ssAAV) or a self-complementary AAV (scAAV), the latter enabling more rapid onset of transgene expression due to its ability to form double- stranded DNA without host-mediated synthesis. According to specific embodiments, the AAV vector is a scAAV.

[0061] According to specific embodiments, the AAV vector comprises a targeting moiety. For example, according to specific embodiments a moiety promoting preferred transduction of T cells. Such a targeting moiety may be associated with, connected to or incorporated into the viral capsid, including by linkage to, fusion with or incorporation within one or more capsid proteins, such as VP1, VP2 and / or VP3, or by replacement or modification thereof.

[0062] Such targeting moieties are known in the art and include for example, a Designed Ankyrin Repeat Protein (DARPin), an antibody, a ligand and / or a peptide mimetic.

[0063] As used herein, the term “DARPin” refers to an engineered protein comprising ankyrin repeat motifs and capable of binding a target molecule with high specificity and affinity. Such DARPins may be selected or engineered to bind to cell surface markers expressed on target immune cells. Methods for generating, engineering, or selecting DARPins are known in the art and include, without limitation, display-based technologies such as phage display, ribosome display, and other in vitro or in vivo selection approaches.

[0064] According to specific embodiments, the DARPin is specific to a T cell marker, including but not limited to CD3, CD4, CD8, L-selectin, PD-L1, or any combination thereof.

[0065] According to specific embodiments, targeting of the AAV vector is refined by capsid engineering strategies. Such strategies include modification or elimination of native receptor binding domains, for example, removal of heparan sulfate proteoglycan (HSPG) binding activity, thereby reducing native tropism and enhancing specificity toward target cells.

[0066] Methods of preparing such AAV vectors are well known in the art (see e.g., U.S. Pat. No.

[0067] 5,173,414; WO 92 / 01070; WO 93 / 03769; WO 2023 / 187779; Lebkowski et al., 1988; Vincent et al., 1990; Carter, 1992; Muzyczka, 1992; Kotin, 1994; Shelling and Smith, 1994; Zhou et al.,1994, Naso NF et al. 2017; Wang D et al. 2019; Wang JH et al. 2024, all of which are incorporated herein by reference).

[0068] As used herein, a “genome integration moiety” refers to a component within an AAV vector or co-delivered in association with an AAV vector that facilitates the stable integration of the heterologous nucleic acid sequence described herein into the genome of an infected cell. Genome integration moieties are well known in the art and include, but are not limited to, homologous sequence elements that mediate site-specific integration via homologous recombination, as well as components that comprise or encode exogenous nucleases or recombinases such as transposases (e.g., Sleeping Beauty, PiggyBac), integrases (e.g., retroviral or lentiviral), site-specific recombinases (e.g., Cre, Flp), and genome editing systems (e.g., CRISPR / Cas9), which promote genomic insertion of heterologous sequences by inducing or exploiting double-stranded DNA breaks.

[0069] As is known in the art, wild-type AAV lacks such elements and typically persists in infected cells as an episome, without stable integration into the host genome. Accordingly, the AAV vectors disclosed herein are designed to avoid genomic integration by excluding components that promote or mediate chromosomal incorporation of the delivered heterologous nucleic acid sequence. This non-integrating profile supports transient expression.

[0070] As used herein, the term “transient” refers to the temporary expression of the heterologous nucleic acid sequence in an infected cell, wherein the nucleic acid is not integrated into the host genome, but rather remains as an episome, distinct from the host genome. In the absence of a genome integration, the delivered nucleic acid persists as an extrachromosomal element that does not replicate with the host genome. It is believed that over time, this leads to the loss of the transgene and transgene expression, with the rate of transgene loss dependent on the turnover rate of the transduced cell population.

[0071] According to some embodiments, the compositions and uses disclosed herein exclude the presence or use of composition, kits and uses that comprise a genome integration moiety in association with the heterologous nucleic acid sequence delivered by the AAV vector described herein, whether within the same vector, in a separate formulation or administered in combination therewith. In particular, embodiments of the invention exclude co-administration, sequential administration or combined use of the AAV vector described herein with components that facilitate genomic integration of the nucleic acid sequence encoding the heterologous immune cell activating transmembrane protein encoded by the AAV vector.

[0072] The AAV vector disclosed herein comprises a nucleic acid sequence encoding a heterologous immune cell activating transmembrane protein.As used herein, the term “heterologous” refers to a nucleic acid sequence or an amino acid sequence which is not native to the recited sequence, vector, host cell or organism, at least in terms of its natural localization or arrangement, or is completely absent therefrom.

[0073] “A nucleic acid encoding”, as used herein, refers to a sequence which encodes an expression product of interest, in this case and according to some embodiments the activating transmembrane protein.

[0074] According to specific embodiments, the expression nucleic acid sequence comprised in the AAV vector has a length of at least about 0.5 kb and up to about 5 kb.

[0075] According to specific embodiments, the expression nucleic acid sequence comprised in the AAV vector has a length of up to about 4.7 kb, up to about 4 kb, up to about 3 kb, or up to about 2.5 kb.

[0076] According to specific embodiments, the expression nucleic acid sequence comprised in the AAV vector has a length of at least about 0.5 kb, at least about 0.8 kb, at least about 1 kb, or at least about 1.5 kb.

[0077] As used herein the phrase “activating transmembrane protein” refers to a recombinant molecule presented on a cell membrane (i.e., cell surface receptor) which comprises an extracellular domain, a transmembrane domain and an intracellular signaling module. The extracellular domain and / or the signaling domain may be covalently attached to the transmembrane domain. According to some embodiments, the extracellular domain binds an antigen expressed by a target immune cell and mediates activation of the cell expressing the protein.

[0078] According to specific embodiments, the activating transmembrane protein is a native receptor; i.e., the extracellular, transmembrane and intracellular domains of the receptor are endogenous to each other. Non-limiting examples of such receptors include, but not limited to T cell receptor (TCR), Fc receptor, cytokine receptor etc.

[0079] According to other specific embodiments, the activating transmembrane protein is a chimeric receptor.

[0080] As used herein, the term “chimeric transmembrane protein” or “chimeric receptor”, also known as “fusion receptor”, refers to a cell surface receptor comprising an amino acid sequence having two or more amino acid sequences which are not found together as a single protein expression product in nature, in other words they are heterologous to one another.

[0081] According To specific embodiments, the activating transmembrane protein is a T cell transmembrane protein, i.e., a transmembrane protein expressed in a T cell and capable of mediating activation of the T cell.As used herein, the terms “activating” or “activation” refer to the initiation of an intracellular signaling processes within a cell that results in a functional cellular response. Such responses may include, but are not limited to, cellular proliferation, differentiation, maturation, secretion of bioactive molecules (such as cytokines, chemokines, or growth factors), chemotaxis, or the execution of effector functions. In certain embodiments, activation occurs in an immune cell (e.g., T cell, NK cell), leading to responses such as cytokine secretion (e.g., IFN-gamma, IL-2, TNF-alpha), antigen specific cytotoxicity and / or clonal expansion.

[0082] As mentioned, the activating transmembrane protein comprises at least an extracellular binding domain and an intracellular signaling module. Non-limiting examples of such activating transmembrane proteins are known in the art and include chimeric antigen receptor (CAR), a chimeric autoantibody receptor (CAAR) and a T cell receptor (TCR), as further described herein.

[0083] According to specific embodiments, the activating transmembrane protein is a CAR. As used herein, a “chimeric antigen receptor (CAR)” is an artificially constructed hybrid protein or polypeptide containing an antigen binding domain of an antibody (e.g., a single chain variable fragment (scFv)) linked to T-cell signaling or T-cell activation domains.

[0084] According to specific embodiments, the activating transmembrane protein is a CAAR. As used herein, a “chimeric autoantibody receptor (CAAR)” is an artificially constructed hybrid protein or polypeptide containing an extracellular domain comprising an autoantigen or fragment thereof, which binds to antibodies expressed by target immune cells, linked to T-cell signaling or T-cell activation domains.

[0085] According to specific embodiments, the activating transmembrane protein is a TCR. As used herein, a “T cell receptor (TCR)” is a transmembrane receptor comprising a heterodimer of a TCR alpha polypeptide and a TCR beta polypeptide, which together form antigen-recognizing domains capable of binding a peptide-major histocompatibility complex (pMHC) presented on a target cell, and are functionally associated with intracellular signaling components that mediate activation of the cell expressing the receptor.

[0086] As used herein, the phrase “antigen expressed by a target immune cell”, refers to a membrane associated molecule that is expressed on an immune cell (e.g., B cell). The skilled artisan will understand that any macromolecule, including virtually all proteins or peptides, as well as carbohydrates, lipids and DNA can serve as an antigen. Methods of determining cell surface presentation are well known in the art and include, but not limited to flow cytometry and immuno-cytochemistry.

[0087] According to specific embodiments, the antigen is over-presented as compared to other cells (e.g., non-immune cell), as determined by flow cytometry or immuno-cytochemistry.According to other embodiment, the antigen is present on the cell surface of the immune cells and absent from other cells (e.g., non-immune cell), as determined by flow cytometry or immuno-cytochemistry.

[0088] According to specific embodiments, the target immune cell is a B cell.

[0089] Antigens expressed by B cells are known to the skilled in the art. Non-limiting examples of such antigens that can be used with specific embodiments of the invention include CD 19, CD20, CD22, CD79a, CD79b, CD21, CD72, CD 180, BAFF receptor (BAFF-R), and the IgE receptor.

[0090] According to specific embodiments, the antigen is CD 19, CD20 and / or IgE receptor. According to specific embodiments, the antigen is CD 19.

[0091] As used herein, the phrase “extracellular binding domain” refers to a moiety that has a binding affinity (e.g., below 10’4M) to a target of interest. Non-limiting examples of binding domains include the binding domain of an antibody, a peptibody, a receptor, a ligand, a hormone, and the like.

[0092] Assays for testing binding are well known in the art and include, but not limited to flow cytometry, bio-layer interferometry Blitz® assay, HPLC, surface plasmon resonance (e.g., Biacore).

[0093] According to specific embodiments, the extracellular binding domain binds the target with a Kd <10-6M, <10-7M, <10-8M or <10-9M, each possibility represents a separate embodiment of the present invention.

[0094] According to specific embodiments, the binding domain is of an antibody.

[0095] The term "antibody" as used in this invention includes intact molecules as well as functional fragments thereof (that are capable of binding to an epitope of an antigen).

[0096] As used herein, the term "epitope" refers to any antigenic determinant on an antigen to which the paratope of an antibody binds. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or carbohydrate side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics.

[0097] According to specific embodiments, the antibody is an antibody fragment.

[0098] According to a specific embodiment, the antibody fragments include, but are not limited to, single chain, Fab, Fab’ and F(ab')2 fragments, Fd, Fcab, Fv, dsFv, scFvs, diabodies, minibodies, nanobodies, Fab expression library or single domain molecules such as VH and VL that are capable of binding to an epitope of the antigen in an HLA restricted manner.Suitable antibody fragments for practicing some embodiments of the invention include a complementarity-determining region (CDR) of an immunoglobulin light chain (referred to herein as “light chain”), a complementarity-determining region of an immunoglobulin heavy chain (referred to herein as “heavy chain”), a variable region of a light chain, a variable region of a heavy chain, a light chain, a heavy chain, an Fd fragment, and antibody fragments comprising essentially whole variable regions of both light and heavy chains such as an Fv, a single chain Fv (scFv), a disulfide- stabilized Fv (dsFv), an Fab, an Fab’, and an F(ab’)2, or antibody fragments comprising the Fc region of an antibody.

[0099] According to specific embodiments, the identity of the amino acid residues in the antibody that make up the variable region and / or the CDRs is determined by the method of Kabat et al. (See, e.g., Kabat et al., 1992, Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, NIH, Washington D.C.).

[0100] Functional antibody fragments comprising whole or essentially whole variable regions of both light and heavy chains are defined as follows:

[0101] (i) Fv, defined as a genetically engineered fragment consisting of the variable region of the light chain (VL) and the variable region of the heavy chain (VH) expressed as two chains;

[0102] (ii) single chain Fv (“scFv”), a genetically engineered single chain molecule including the variable region of the light chain and the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule.

[0103] (iii) disulfide-stabilized Fv (“dsFv”), a genetically engineered antibody including the variable region of the light chain and the variable region of the heavy chain, linked by a genetically engineered disulfide bond.

[0104] (iv) Fab, a fragment of an antibody molecule containing a monovalent antigen-binding portion of an antibody molecule which can be obtained by treating whole antibody with the enzyme papain to yield the intact light chain and the Fd fragment of the heavy chain which consists of the variable and CHI domains thereof;

[0105] (v) Fab’, a fragment of an antibody molecule containing a monovalent antigen-binding portion of an antibody molecule which can be obtained by treating whole antibody with the enzyme pepsin, followed by reduction (two Fab’ fragments are obtained per antibody molecule);

[0106] (vi) F(ab’)2, a fragment of an antibody molecule containing a monovalent antigenbinding portion of an antibody molecule which can be obtained by treating whole antibody with the enzyme pepsin (i.e., a dimer of Fab’ fragments held together by two disulfide bonds);

[0107] (vii) Single domain antibodies or nanobodies are composed of a single VH or VL domains which exhibit sufficient affinity to the antigen; and(viii) Fcab, a fragment of an antibody molecule containing the Fc portion of an antibody developed as an antigen-binding domain by introducing antigen-binding ability into the Fc region of the antibody.

[0108] According to specific embodiments, the extracellular binding domain capable of binding the target comprises a scFv.

[0109] Methods of producing polyclonal and monoclonal antibodies as well as fragments thereof are well known in the art (See for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1988, incorporated herein by reference).

[0110] It will be appreciated that for human therapy, humanized antibodies are preferably used. According to specific embodiments, the antibody is a humanized antibody. Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab').sub.2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues form a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].

[0111] Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as import residues, which are typically taken from an import variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of ahuman antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Pat. No.

[0112] 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

[0113] According to specific embodiments, the antibody is a human antibody.

[0114] Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J. Immunol., 147(l):86-95 (1991)]. Similarly, human antibodies can be made by introduction of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio / Technology 10,: 779-783 (1992); Lonberg et al., Nature 368: 856-859 (1994); Morrison, Nature 368 812-13 (1994); Fishwild et al., Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14: 826 (1996); and Lonberg and Huszar, Intern. Rev. Immunol. 13, 65-93 (1995).

[0115] According to specific embodiments, the extracellular domain is an anti-CD19 or anri-CD20 antibody.

[0116] Non-limiting examples of anti-CD19 antibodies that can be used to generate such binding domains include FMC63, SJ25C1 and 4G7 and humanized variants thereof.

[0117] Non-limiting examples of anti-CD20 antibodies that can be used to generate such binding domains include rituximab, ofatumumab, obinutuzumab and veltuzumab.

[0118] Such antibodies or antigen-binding fragments or derivatives thereof, have been widely used or proposed for use in CAR constructs, see e.g., W02012079000, W02019028051, US 10669349 and US7435803. Additional examples include CAR constructs utilized in therapies such as tisagenlecleucel (Kymriah®), axicabtagene ciloleucel (Yescarta®), brexucabtagene autoleucel (Tecartus®), lisocabtagene maraleucel (Breyanzi®), idecabtagene vicleucel (Abecma®), and ciltacabtagene autoleucel (Carvykti®), or antigen-binding domains derived therefrom.According to specific embodiments, the extracellular binding domain is of a ligand and the target is a receptor of the ligand. Non-limiting examples of such ligand - receptor pairs that can be used with some embodiments of the invention include cytokine-cytokine receptor pairs, chemokine-chemokine receptor pairs and immune checkpoint ligand-receptor pairs According to other specific embodiments, the extracellular binding domain is of a receptor and the target is a ligand of the receptor. Non-limiting examples of such receptor -ligand pairs that can be used with some embodiments of the invention include TCR - peptide-major histocompatibility complex.

[0119] According to further specific embodiments, the extracellular binding domain comprises an antigen and the target is an antibody on the target cell. Non-limiting examples of such systems include chimeric autoantibody receptor (CAAR) constructs, for example as described in EP3166968, the contents of which are incorporated herein by reference.

[0120] Additional examples of extracellular binding domains that can be used with specific embodiments of the invention as described in Ramirez-Chacon A, et al. Front Immunol. 2022 Sep 12;13:932559. doi: 10.3389 / fimmu.2022.932559, the contents of which are fully incorporated herein by reference.

[0121] According to specific embodiments, the extracellular domain comprises at least one hinge region. The hinge region, as used herein, is a flexible amino acid stretch / structure, which may in some embodiments link between the target- binding domain and the transmembrane domain. In some embodiments, the hinge-region is rich in cysteine and proline amino acids. Non-limiting examples of hinge regions that can be used with specific embodiments of the invention are derived from IgG (e.g., IgGl or IgG4), IgD, CDS or CD28 molecules, their sequences are well known to the skilled in the art.

[0122] As used herein, the phrase “intracellular signaling module” refers to an intracellular portion of the receptor which initiates a signaling cascade following binding of the extracellular binding domain to its target to thereby transduce the effector function signal and direct the cell to perform a specialized function. Methods of determining signaling in cells are well known in the art and include, but not limited to enzymatic activity assays such as kinase activity assays, and expression of molecules involved in the signaling cascade using e.g., PCR, Western blot, immunoprecipitation and immunohistochemistry. Additionally or alternatively, determining signaling can be effected by evaluating cell activation or function by methods well known in the art such as, but not limited to proliferation assays such as CFSE staining, MTT, Alamar blue, BRDU and thymidine incorporation, cytotoxicity assays such as CFSE staining, chromium release, Calcin AM, cytokine secretion assays such as intracellular cytokine staining, EEISPOTand ELISA, expression of activation markers (in T cell for example markers such as CD25, CD69, CD137, CD107a, PD1, and CD62L) using flow cytometry, and the like.

[0123] Such signaling domains are well known in the art and non-limiting examples are further provided in details infra.

[0124] According to specific embodiments, the intracellular signaling domain comprises an immunoreceptor tyrosine-based activation motif (ITAM). Non-limiting examples of ITAM containing signaling sequences include those derived from a T cell receptor (TCR) e.g., CD3 zeta, CD3 gamma, CD3 delta, CD3 epsilon; Fc receptor e.g., FcR gamma, FcR beta; CD5; CD22; CD79a; CD79b; and CD66d, their sequences are well known to the skilled in the art.

[0125] According to specific embodiments, the intracellular domain comprises an intracellular domain of CD3zeta.

[0126] According to specific embodiments, the intracellular signaling domain comprises a costimulatory receptor signaling domain.

[0127] As used herein, the phrase “co-stimulatory receptor signaling domain” refers to an amino acid sequence of a co-stimulatory molecule capable of transmitting a secondary stimulatory signal resulting in activation of an immune cell (e.g., T cell). Typically, a co-stimulatory signaling domain does not comprise an ITAM domain. Any known co-stimulatory signaling domain can be used with specific embodiments of the present invention. Non-limiting examples of co-stimulatory signaling domains include CD28, 4-1BB, 0X40, ICOS, CD27, GITR, HVEM, TIM1, LFAl(CDlla), CD2, their sequences are well known to the skilled in the art.

[0128] According to specific embodiments, the co-stimulatory molecule is CD28.

[0129] According to specific embodiments, the intracellular signaling domain comprises a cytokine receptor signaling domain.

[0130] As used herein, the phrase “cytokine receptor signaling domain” refers to an amino acid sequence of a cytokine receptor capable of transmitting a stimulatory signal resulting in activation of the immune cell (e.g., T cell). Any known cytokine receptor signaling domain can be used with specific embodiments of the present invention. Non-limiting examples of cytokine receptor signaling domains include those from IL-2R (e.g. IL2Ra, IL2Rb, or IL2Ry that is the IL2 receptor common gamma chain), the Toll / ILl receptor homology domain (TIR) that is the signaling domain of the myd88 receptor, TNF receptor intracellular domain, IL12-Rbl intracellular domain, IL12-Rbl intracellular domain, IL23 receptor intracellular domain, IFNy receptor 1 intracellular domain, IFNy receptor 2 intracellular domain, IL1 receptor intracellular domain, ILlAcP receptor intracellular domain, their sequences are well known to the skilled in the art.The activating transmembrane protein disclosed herein further comprises a transmembrane domain.

[0131] According to specific embodiments, the transmembrane domain is heterologous to the extracellular binding domain and / or the intracellular signaling domain.

[0132] According to specific embodiments, the transmembrane domain is endogenous to the extracellular binding domain.

[0133] According to specific embodiments, the transmembrane domain is endogenous to the intracellular signaling domain.

[0134] Non-limiting examples of transmembrane domains that can be used with specific embodiments of the invention include an alpha, beta or zeta chain of a T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD27, CD28, CD33, CD37, CD64, CD80, CD86, CD134, CD137 (4-1BB), TNFSFR25, CD154 and IL-2R, their sequences are well known to the skilled in the art.

[0135] According to specific embodiments, the transmembrane domain is of a protein selected from the group consisting of CD8 and CD28.

[0136] A non-limiting example of an immune cell activating transmembrane protein encompassed by specific embodiments of the invention comprises an extracellular binding domain of an antibody (e.g., anti-CD19 scFV), a transmembrane domain of CD28 and an intracellular signaling of CD3zeta. An exemplary sequence of such an immune cell activating transmembrane protein suitable for use with specific embodiments of the invention is provided in SEQ ID NO: 18 (comprising a GM-CSF signal peptide, an anti-CD19 scFv in a VL-linker-VH orientation, a CD28 transmembrane domain and a CD3^ intracellular signaling domain).

[0137] As used herein, the term "regulatory element for directing expression of the nucleic acid sequence” or “expression regulatory element” refers to a cis-acting nucleic acid sequence that modulates transcription of an operably linked coding nucleic acid sequence via binding of one or more transcription factors (TFs). Expression regulatory elements include, but are not limited to, promoters and enhancers, each comprising one or more transcription factor binding motifs.

[0138] The term "operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. For instance, a promoter is operably linked to a coding sequence if the promoter affects its transcription or expression. Operably linked nucleic acid sequences may but need not necessarily be adjacent. For example, in some instances a coding sequence operably linked to a promoter may be adjacent to the promoter. In some instances, a coding sequence operably linked to a promoter may be separated by one or more intervening sequences, including coding and non-codingsequences. Also, in some instances, more than two sequences may be operably linked including but not limited to e.g., where two or more coding sequences are operably linked to a single promoter.

[0139] It should be appreciated that the regulatory element suitable for the present invention may be either endogenous or heterologous to the nucleic acid sequence whose expression it regulates

[0140] According to specific embodiments, the regulatory element is heterologous to the nucleic acid sequence whose expression it regulates.

[0141] Cis-acting regulatory sequences include those that direct constitutive expression of a nucleotide sequence as well as those that direct inducible expression of the nucleotide sequence only under certain conditions.

[0142] According to specific embodiments, the cis-acting regulatory element comprises a promoter.

[0143] According to specific embodiments, the promoter is a constitutive promoter.

[0144] Non-limiting examples of constitutive promoters suitable for use with some embodiments of the invention are promoter sequences which are active under most environmental conditions and most types of cells such as the cytomegalovirus (CMV) promoter, Rous sarcoma virus (RSV) promoter, elongation factor 1 alpha (EFla) promoter, phosphoglycerate kinase (PGK) promoter, murine stem cell virus (MSCV) promoter and a JeT promoter

[0145] According to specific embodiments, the promoter is selected from the group consisting of PGK, EFla and MSCV.

[0146] According to other specific embodiments, the promoter is an inducible promoter.

[0147] Non-limiting examples of inducible promoters suitable for use with some embodiments of the invention include for example the tetracycline-regulated promoter systems (e.g., TetON, TetOFF), steroid-responsive promoter systems (e.g., glucocorticoid receptor-, estrogen receptor-, retinoid-, thyroid hormone-, or ecdysone -responsive systems), metal-regulated promoters (e.g., metallothionein promoter systems) and heat shock-inducible promoters (e.g., HSP70, HSP90).

[0148] According to specific embodiments, the promoter is an immune cell specific promoter that is expressed in one or more immune cell types, including but not limited to lymphocytes, hematopoietic stem cells and / or progeny thereof (i.e., immune cell progenitors). According to specific embodiments, the immune cell specific promoter is a T cell specific promoter. Examples of T cell specific promoters include lymphoid specific promoters [Calame et al., (1988) Adv. Immunol. 43:235-275]; in particular promoters of T cell receptor genes [Winoto et al., (1989) EMBO J. 8:729-733], as well as CD3, CD4, and CD8 gene promoters. In someinstances, the immune cell specific promoter is an immunoglobulin gene promoter, including light and / or heavy chain immunoglobulin promoters. In some embodiments, the promoter is a viral promoter capable of driving expression in immune cells. Non-limiting examples of such promoters include lentiviral long terminal repeat (LTR) promoters (e.g., HIV, SIV, FIV, EIAV, or Visna virus LTRs) and other retroviral promoters, including human T-cell leukemia virus (HTLV-I and HTLV-II) promoters.

[0149] According to specific embodiments, the promoter is a strong promoter.

[0150] Non-limiting examples of such promoters are PGK promoter, EFla promoter, SFFV promoter and CMV promoter.

[0151] According to other specific embodiments, the promoter is a weak promoter.

[0152] Non-limiting examples of such promoters are minimal promoters (also known as core promoters) with low baseline activity, such as the minimal TATA-box promoter and the minimal CMV promoter.

[0153] Typically, such minimal promoters need one or more related enhancer elements to induce robust gene expression. A detailed description on such promoters is provided in Zabidi MA and Stark A. Trends Genet. 2016 Dec;32(12):801-814. doi: 10.1016 / j.tig.2016.10.003. Epub 2016 Nov 2. PMID: 27816209; PMCID: PMC6795546, the contents of which are fully incorporated herein by reference.

[0154] According to specific embodiments, the cis-acting regulatory element comprises an enhancer.

[0155] Enhancer elements suitable for use with some embodiments of the invention include sequences that increase transcriptional activity and may function in a wide range of cell types. For example, the simian virus 40 (SV40) early gene enhancer is active in many cell types. Other enhancer elements include those derived from polyoma virus, human or murine cytomegalovirus (CMV), and long terminal repeat (LTR) regions of retroviruses such as murine leukemia virus (MLV), Rous sarcoma virus (RSV), and human immunodeficiency virus (HIV). Additional enhancer elements and enhancer / promoter combinations suitable for use with the present invention are well known in the art (see, e.g., Enhancers and Eukaryotic Expression, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1983), the contents of which are incorporated herein by reference.

[0156] In addition, the nucleic acid construct comprised within the AAV vector may further include other transcriptional and translational regulatory elements, such as a transcription and translation initiation sequence, transcription and translation termination sequence and a polyadenylation signal, the construct being flanked by inverted terminal repeats (ITRs) asdescribed herein. By way of example, such constructs will typically include a 5' LTR, a tRNA binding site, a packaging signal, an origin of second-strand DNA synthesis, and a 3' LTR or a portion thereof.

[0157] According to specific embodiments, the nucleic acid sequence comprises a polyadenylation signal.

[0158] Polyadenylation signals suitable for use with some embodiments of the invention include sequences that facilitate transcription termination and polyadenylation of mRNA, thereby enhancing mRNA stability and expression. Typically, two distinct sequence elements are required for accurate and efficient polyadenylation: GU or U rich sequences located downstream from the polyadenylation site and a highly conserved sequence of six nucleotides, AAUAAA, located 11-30 nucleotides upstream. Termination and polyadenylation signals that are suitable for some embodiments of the invention include those derived from SV40 or BGH.

[0159] The nucleic acid construct comprised within the AAV vector of some embodiments of the invention may also include or encode a signal sequence for targeting the polypeptide to the desired site in a cell. Such sequences are known in the art. According to a specific embodiment, the signal sequence is a mammalian signal sequence or the signal sequence of the polypeptide variants of some embodiments of the invention. According to specific embodiments the signal sequence comprises a membrane trafficking sequence. Non-limiting examples of such include the signal peptides derived from membrane-bound or secreted mammalian proteins, including CD8, CD28, interleukin-2 (IL-2), GM-CSF, immunoglobulin light chain (IgK) or immunoglobulin heavy chain. According to specific embodiments, the signal sequence is a CD8a leader sequence.

[0160] According to specific embodiments, the AAV vector comprises a nucleic acid sequence encoding an additional heterologous expression product, as further described infra.

[0161] More specifically, according to some embodiments, the vector further encodes a therapeutic agent. The inclusion of such additional expression products is consistent with approaches developed in advanced CAR T cell systems, such as “fourth generation” CAR T cells (TRUCKs; T cells redirected for antigen-unrestricted cytokine-initiated killing), in which engineered cells are configured not only for antigen- specific targeting but also for delivery of immune-modulating agents, for example cytokines, to modulate the local immune environment.

[0162] The therapeutic agent may be a polynucleotide agent or a protein agent (e.g., peptides, polypeptides and proteins). Non-limiting examples of therapeutic agents that can be used with specific embodiments of the invention include antibodies, Fc-fusions, T cell engagers, toxins, cytokines, chemokines, growth factors, immune check point molecules, hormones, enzymes,miRs, aptamers, RNA silencing agents [e.g., antisense oligonucleotides (ASOs), RNA interference (RNAi)] and the like. Selection of the therapeutic agent used is well within the capabilities of those skilled in the art, and depends on the type of the pathology.

[0163] In order to assess expression, the expression vector can also contain either a selectable marker gene or a reporter gene or both to facilitate identification and selection of expressing cells from the population of cells sought to be transfected or transduced through the viral vector.

[0164] Thus, according to specific embodiments, the vector further encodes a detectable agent. Detectable agents suitable for use herein are known in the art and include, without limitation, reporter proteins and affinity tags. Non-limiting examples include fluorescent proteins (e.g., GFP) and affinity tags such as His-tag, FLAG-tag, HA-tag, Myc-tag (e.g., c-Myc tag), Strep-tag, HaloTag, or combinations thereof.

[0165] In order to enable controlled elimination or modulation of cells expressing the heterologous nucleic acid sequence, the vector may further comprise a safety switch.

[0166] Thus, according to specific embodiments, the vector further encodes a safety switch. As used herein, the term “safety switch” refers to a genetic element that enables selective control over the survival, activity or persistence of cells expressing the nucleic acid sequence of interest, for example in response to an external stimulus.

[0167] In some embodiments, the safety switch comprises an inducible control system that regulates the activity or persistence of the encoded product or of cells expressing the product in response to an external stimulus. Such systems include, without limitation, ligand- or druginducible regulatory domains, chemically inducible dimerization systems or other controllable protein-level regulatory mechanisms.

[0168] According to specific embodiments, the safety switch comprises a suicide gene. As used herein, the term “suicide gene” refers to a gene encoding a protein that promotes or induces cell death in cells expressing the gene. Suicide genes suitable for use with some embodiments of the invention include, without limitation, caspases (e.g., CASP3, CASP8, CASP9), pro-apoptotic proteins such as BAX and DFF40, and death receptor-associated molecules such as Fas. Further examples include genes encoding cytotoxic proteins or enzymes that produce cytotoxic metabolites, such as abrin, ricin A, Pseudomonas exotoxin, cholera toxin, diphtheria toxin, herpes simplex virus thymidine kinase (HSV-TK), and cytidine deaminase. Additional examples include genes that render cells susceptible to antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). In some embodiments, the suicide gene is inducible. For example, inducible caspase systems such as inducible caspase-9 (iCasp9),comprising a caspase fused to a dimerization domain, may be employed, wherein activation of the dimerization domain induces apoptosis of the transduced cell.

[0169] According to specific embodiments, the immune cell activating transmembrane protein and the additional heterologous expression product are encoded by separate nucleic acid constructs comprised within the same AAV vector.

[0170] According to other specific embodiments, the immune cell activating transmembrane protein and the additional heterologous expression product are expressed from a single construct in a multicistronic e.g., bicistronic manner. Such an expression can be achieved by methods well known in the art such as, but not limited to, using internal ribosome entry site (IRES) sequence and / or a nucleic acid sequence encoding a self-cleavable peptide e.g., a 2A peptide (e.g., P2A, T2A, E2A).

[0171] According to a specific embodiment, the immune cell activating transmembrane protein and the additional heterologous expression product are transcribed from different cis-acting regulatory elements operatively attached therewith.

[0172] Further, for maximal protein expression, specific embodiments contemplate adaptation of codons of the transcript gene to the typical codon usage of a host e.g., a human. In this aspect, many synthetic genes can be designed to increase their protein expression level. The design process of codon optimization can be to alter rare codons to codons known to increase maximum protein expression efficiency. In some alternatives, codon selection is described, wherein codon selection can be performed by using algorithms to create synthetic genetic transcripts optimized for high protein yield. Programs containing algorithms for codon optimization are available and include e.g., OptimumGene™, and GeneGPSR™. In some alternatives of the methods provided herein, the vectors provided for the methods are codon optimized for expression in humans.

[0173] As mentioned, the nucleic acid construct comprised in the AAV vector of some embodiments of the invention can further include additional polynucleotide sequences that allow, for example, the translation of several proteins from a single mRNA such as an internal ribosome entry site (IRES) or a self-cleavable peptide.

[0174] It will be appreciated that the individual elements comprised in the nucleic acid construct can be arranged in a variety of configurations. For example, enhancer elements, promoters and the like, and even the polynucleotide sequence(s) encoding the polypeptide can be arranged in a "head-to-tail" configuration, may be present as an inverted complement, or in a complementary configuration, as an anti-parallel strand. While such variety of configuration is more likely to occur with non-coding elements of the expression vector, alternative configurations of the coding sequence within the expression vector are also envisioned.Any of the components comprised in a single polynucleotide or polypeptide (e.g., the immune cell activating transmembrane protein) as described herein may be linked to each other directly of via a linker, each possibility represents a separate embodiment of the present invention.

[0175] Suitable linkers include any polynucleotide or polypeptide linker known in the art. According to specific embodiments, the linker may be derived from naturally-occurring multidomain proteins or is an empirical linker as described, for example, in Chichili et al., (2013), Protein Sci. 22(2): 153-167, Chen et al, (2013), Adv Drug Deliv Rev. 65(10): 1357-1369, the entire contents of which are hereby incorporated by reference. In some embodiments, the linker may be designed using linker designing databases and computer programs such as those described in Chen et al., (2013), Adv Drug Deliv Rev. 65(10): 1357-1369 and Crasto et al., (2000), Protein Eng. 13(5):309-312, the entire contents of which are hereby incorporated by reference.

[0176] According to specific embodiments, any of the genes, polynucleotides, proteins, polypeptides and / or proteinaceous moieties described herein may have a sequence of a human gene, polynucleotide, protein, polypeptide and / or proteinaceous moiety or a functional fragment or homolog thereof which exhibit the desired activity as described herein.

[0177] According to specific embodiments, the gene, polynucleotide, protein, polypeptide and / or proteinaceous moiety is of a human origin.

[0178] According to other specific embodiments, the gene, polynucleotide, protein, polypeptide and / or proteinaceous moiety is a homolog of a human gene, polynucleotide, protein, polypeptide and / or proteinaceous moiety. Such homologues can be, for example, at least 70 %, at least 75 %, at least 80 %, at least 81 %, at least 82 %, at least 83 %, at least 84 %, at least 85 %, at least 86 %, at least 87 %, at least 88 %, at least 89 %, at least 90 %, at least 91 %, at least 92 %, at least 93 %, at least 94 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical or homologous to the human sequence.

[0179] According to specific embodiments, the sequence of any of the genes, polynucleotides, proteins, polypeptides and / or proteinaceous moieties described herein may refer to a fragment or a homolog of the amino acid sequence or nucleic acid sequence disclosed herein which exhibit the desired activity as defined herein. The homolog (naturally occurring or synthetically / recombinantly produced) can be, for example, at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, at least 85 %, at least 90 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical or homologous to the polypeptide sequence provided herein or a functional fragment thereof whichexhibit the desired activity as defined herein; or at least 50 %, at least 55 %, at least 60 %, at least 65 %, at least 70 %, at least 75 %, at least 80 %, at least 85 %, at least 90 %, at least 95 %, at least 96 %, at least 97 %, at least 98 %, at least 99 % or 100 % identical to the polynucleotide sequence encoding same.

[0180] Sequence identity or homology can be determined using any protein or nucleic acid sequence alignment algorithm such as Blast, ClustalW, and MUSCLE.

[0181] The homolog may also refer to an ortholog, a deletion, insertion, or substitution variant, including a conservative and non-conservative amino acid substitution, as further described hereinbelow.

[0182] The present disclosure further provides methods and uses of the compositions described herein for treatment in a subject in need thereof.

[0183] According to an aspect of the present invention there is provided a method of treating an autoimmune disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the composition disclosed herein, thereby treating the autoimmune disease in the subject.

[0184] According to an additional or an alternative aspect of the present invention, there is provided the composition disclosed herein for use in treating an autoimmune disease in a subject in need thereof.

[0185] As used herein, the term “treating” includes abrogating, substantially inhibiting, slowing or reversing the progression of a condition, substantially ameliorating clinical or aesthetical symptoms of a condition or substantially preventing the appearance of clinical or aesthetical symptoms of a condition.

[0186] As used herein, the term “subject” includes mammals, preferably human beings at any age or gender. The subject may be healthy or showing signs of a pathology. This term also encompasses individuals who are at risk to develop the pathology. According to specific embodiments the subject is diagnosed with the pathology.

[0187] Autoimmune diseases encompassed by specific embodiments of the invention include, but are not limited to, cardiovascular diseases, rheumatoid diseases, glandular diseases, gastrointestinal diseases, cutaneous diseases, hepatic diseases, neurological diseases, muscular diseases, nephric diseases, diseases related to reproduction, connective tissue diseases and systemic diseases.

[0188] Examples of autoimmune cardiovascular diseases include, but are not limited to atherosclerosis (Matsuura E. et al., Lupus. 1998;7 Suppl 2:S 135), myocardial infarction (Vaarala O. Lupus. 1998;7 Suppl 2:S 132), thrombosis (Tincani A. et al., Lupus 1998;7 Suppl 2:S 107-9),Wegener’s granulomatosis, Takayasu’s arteritis, Kawasaki syndrome (Praprotnik S. et al., Wien Klin Wochenschr 2000 Aug 25; 112 (15-16):660), anti-factor VIII autoimmune disease (Lacroix-Desmazes S. et al., Semin Thromb Hemost.2000;26 (2): 157), necrotizing small vessel vasculitis, ANCA-associated vasculitis, microscopic polyangiitis, Churg and Strauss syndrome, pauci-immune focal necrotizing and crescentic glomerulonephritis (Noel LH. Ann Med Interne (Paris).

[0189] 2000 May; 151 (3): 178), antiphospholipid syndrome (Flamholz R. et al., J Clin Apheresis 1999; 14 (4): 171), antibody-induced heart failure (Wallukat G. et al., Am J Cardiol. 1999 Jun 17;83 (12A):75H), thrombocytopenic purpura (Moccia F. Ann Ital Med Int. 1999 Apr-Jun;14 (2): 114; Semple JW. et al., Blood 1996 May 15;87 (10):4245), autoimmune hemolytic anemia (Efremov DG. et al., Leuk Lymphoma 1998 Jan;28 (3-4):285; Sallah S. et al., Ann Hematol 1997 Mar;74 (3): 139), cardiac autoimmunity in Chagas’ disease (Cunha-Neto E. et al., J Clin Invest 1996 Oct 15;98 (8): 1709) and anti-helper T lymphocyte autoimmunity (Caporossi AP. et al., Viral Immunol 1998;11 (1):9).

[0190] Examples of autoimmune rheumatoid diseases include, but are not limited to rheumatoid arthritis (Krenn V. et al., Histol Histopathol 2000 Jul;15 (3):791; Tisch R, McDevitt HO. Proc Natl Acad Sci units S A 1994 Jan 18;91 (2):437) and ankylosing spondylitis (Jan Voswinkel et al., Arthritis Res 2001; 3 (3): 189).

[0191] Examples of autoimmune glandular diseases include, but are not limited to, pancreatic disease, Type I diabetes, thyroid disease, Graves’ disease, thyroiditis, spontaneous autoimmune thyroiditis, Hashimoto’s thyroiditis, idiopathic myxedema, ovarian autoimmunity, autoimmune anti-sperm infertility, autoimmune prostatitis and Type I autoimmune polyglandular syndrome, diseases include, but are not limited to autoimmune diseases of the pancreas, Type 1 diabetes (Castano L. and Eisenbarth GS. Ann. Rev. Immunol. 8:647; Zimmet P. Diabetes Res Clin Pract 1996 Oct;34 Suppl:S125), autoimmune thyroid diseases, Graves’ disease (Orgiazzi J. Endocrinol Metab Clin North Am 2000 Jun;29 (2):339; Sakata S. et al., Mol Cell Endocrinol 1993 Mar;92 (1):77), spontaneous autoimmune thyroiditis (Braley-Mullen H. and Yu S, J Immunol 2000 Dec 15;165 (12):7262), Hashimoto’s thyroiditis (Toyoda N. et al., Nippon Rinsho 1999 Aug;57 (8): 1810), idiopathic myxedema (Mitsuma T. Nippon Rinsho. 1999 Aug;57 (8): 1759), ovarian autoimmunity (Garza KM. et al., J Reprod Immunol 1998 Feb;37 (2):87), autoimmune antisperm infertility (Diekman AB. et al., Am J Reprod Immunol. 2000 Mar;43 (3): 134), autoimmune prostatitis (Alexander RB. et al., Urology 1997 Dec;50 (6):893) and Type I autoimmune polyglandular syndrome (Hara T. et al., Blood. 1991 Mar 1;77 (5): 1127).

[0192] Examples of autoimmune gastrointestinal diseases include, but are not limited to, chronic inflammatory intestinal diseases (Garcia Herola A. et al., Gastroenterol Hepatol. 2000 Jan;23(1): 16), celiac disease (Landau YE. and Shoenfeld Y. Harefuah 2000 Jan 16; 138 (2): 122), colitis, ileitis and Crohn’s disease.

[0193] Examples of autoimmune cutaneous diseases include, but are not limited to, autoimmune bullous skin diseases, such as, but are not limited to, pemphigus vulgaris, bullous pemphigoid and pemphigus foliaceus.

[0194] Examples of autoimmune hepatic diseases include, but are not limited to, hepatitis, autoimmune chronic active hepatitis (Franco A. et al., Clin Immunol Immunopathol 1990 Mar;54 (3):382), primary biliary cirrhosis (Jones DE. Clin Sci (Colch) 1996 Nov;91 (5):551; Strassburg CP. et al., Eur J Gastroenterol Hepatol. 1999 Jun; 11 (6):595) and autoimmune hepatitis (Manns MP. J Hepatol 2000 Aug;33 (2):326).

[0195] Examples of autoimmune neurological diseases include, but are not limited to, multiple sclerosis (Cross AH. et al., J Neuroimmunol 2001 Jan 1 ; 112 (1-2): 1), Alzheimer’s disease (Oron L. et al., J Neural Transm Suppl. 1997;49:77), myasthenia gravis (Infante AJ. And Kraig E, Int Rev Immunol 1999;18 (l-2):83; Oshima M. et al., Eur J Immunol 1990 Dec;20 (12):2563), neuropathies, motor neuropathies (Kornberg AJ. J Clin Neurosci. 2000 May;7 (3): 191); Guillain-Barre syndrome and autoimmune neuropathies (Kusunoki S. Am J Med Sci. 2000 Apr;319 (4):234), myasthenia, Lambert-Eaton myasthenic syndrome (Takamori M. Am J Med Sci. 2000 Apr;319 (4):204); paraneoplastic neurological diseases, cerebellar atrophy, paraneoplastic cerebellar atrophy and stiff-man syndrome (Hiemstra HS. et al., Proc Natl Acad Sci units S A 2001 Mar 27;98 (7):3988); non-paraneoplastic stiff man syndrome, progressive cerebellar atrophies, encephalitis, Rasmussen’s encephalitis, amyotrophic lateral sclerosis, Sydeham chorea, Gilles de la Tourette syndrome and autoimmune polyendocrinopathies (Antoine JC. and Honnorat J. Rev Neurol (Paris) 2000 Jan;156 (1):23); dysimmune neuropathies (Nobile- Orazio E. et al., Electroencephalogr Clin Neurophysiol Suppl 1999;50:419); acquired neuromyotonia, arthrogryposis multiplex congenita (Vincent A. et al., Ann N Y Acad Sci. 1998 May 13;841 :482), neuritis, optic neuritis (Soderstrom M. et al., J Neurol Neurosurg Psychiatry 1994 May;57 (5):544) and neurodegenerative diseases.

[0196] Examples of autoimmune muscular diseases include, but are not limited to, myositis, autoimmune myositis and primary Sjogren’s syndrome (Feist E. et al., Int Arch Allergy Immunol 2000 Sep;123 (1):92), Idiopathic Inflammatory Myositis (IIM), and smooth muscle autoimmune disease (Zauli D. et al., Biomed Pharmacother 1999 Jun;53 (5-6):234).

[0197] Examples of autoimmune nephric diseases include, but are not limited to, nephritis and autoimmune interstitial nephritis (Kelly CJ. J Am Soc Nephrol 1990 Aug;l (2): 140).Examples of autoimmune diseases related to reproduction include, but are not limited to, repeated fetal loss (Tincani A. et al., Lupus 1998;7 Suppl 2:S 107-9).

[0198] Examples of autoimmune connective tissue diseases include, but are not limited to, ear diseases, autoimmune ear diseases (Yoo TJ. et al., Cell Immunol 1994 Aug;157 (1):249) and autoimmune diseases of the inner ear (Gloddek B. et al., Ann N Y Acad Sci 1997 Dec 29;830:266).

[0199] Examples of autoimmune systemic diseases include, but are not limited to, systemic lupus erythematosus (Erikson J. et al., Immunol Res 1998; 17 (l-2):49), Sjogren’s syndrome and systemic sclerosis (Renaudineau Y. et al., Clin Diagn Lab Immunol. 1999 Mar;6 (2): 156); Chan OT. et al., Immunol Rev 1999 Jun; 169: 107).

[0200] According to specific embodiments, the autoimmune disease is selected from the group consisting of systemic lupus erythematosus (SLE), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Myasthenia Gravis (MG), Multiple Sclerosis (MS), Sjogren’s Syndrome (SjD), Rheumatoid Arthritis (RA) and Pemphigus Vulgaris.

[0201] According to specific embodiments, the autoimmune disease is a B cell-mediated autoimmune disease.

[0202] As used herein, “B cell-mediated autoimmune disease” refers to a disease in which B cells (e.g., autoreactive B cells) and / or antibodies produced thereby play a role in disease initiation or progression.

[0203] Non-limiting examples of such diseases include systemic lupus erythematosus (SLE), Sjogren’s syndrome (SjD), myasthenia gravis (MG), rheumatoid arthritis (RA), autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), pemphigus vulgaris, bullous pemphigoid, antiphospholipid syndrome (APS), and ANCA-associated vasculitis.

[0204] According to specific embodiments, the autoimmune disease is systemic lupus erythematosus (SLE).

[0205] The composition comprising the AAV vector disclosed herein can be administered to the individual per se or as part of a pharmaceutical composition which also includes a physiologically acceptable carrier. The purpose of a pharmaceutical composition is to facilitate administration of the active ingredient to an organism.

[0206] As used herein a "pharmaceutical composition" refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.Herein the term "active ingredient" refers to the AAV vector comprising the nucleic acid sequence accountable for the biological effect.

[0207] Hereinafter, the phrases "physiologically acceptable carrier" and "pharmaceutically acceptable carrier" which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound. An adjuvant is included under these phrases.

[0208] Herein the term "excipient" refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.

[0209] Techniques for formulation and administration of drugs may be found in “Remington’s Pharmaceutical Sciences,” Mack Publishing Co., Easton, PA, latest edition, which is incorporated herein by reference.

[0210] Suitable routes of administration may, for example, include oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intracardiac, e.g., into the right or left ventricular cavity, into the common coronary artery, intravenous, intraperitoneal, intranasal, or intraocular injections.

[0211] According to specific embodiments, the composition is administered intravenously.

[0212] Conventional approaches for drug delivery to the central nervous system (CNS) include: neurosurgical strategies (e.g., intracerebral injection or intracerebroventricular infusion); molecular manipulation of the agent (e.g., production of a chimeric fusion protein that comprises a transport peptide that has an affinity for an endothelial cell surface molecule in combination with an agent that is itself incapable of crossing the BBB) in an attempt to exploit one of the endogenous transport pathways of the BBB; pharmacological strategies designed to increase the lipid solubility of an agent (e.g., conjugation of water-soluble agents to lipid or cholesterol carriers); and the transitory disruption of the integrity of the BBB by hyperosmotic disruption (resulting from the infusion of a mannitol solution into the carotid artery or the use of a biologically active agent such as an angiotensin peptide). However, each of these strategies has limitations, such as the inherent risks associated with an invasive surgical procedure, a size limitation imposed by a limitation inherent in the endogenous transport systems, potentially undesirable biological side effects associated with the systemic administration of a chimeric molecule comprised of a carrier motif that could be active outside of the CNS, and the possiblerisk of brain damage within regions of the brain where the BBB is disrupted, which renders it a suboptimal delivery method.

[0213] Alternately, one may administer the pharmaceutical composition in a local rather than systemic manner, for example, via injection of the pharmaceutical composition directly into a tissue region of a patient.

[0214] Pharmaceutical compositions of some embodiments of the invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

[0215] Pharmaceutical compositions for use in accordance with some embodiments of the invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

[0216] For injection, the active ingredients of the pharmaceutical composition may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank’s solution, Ringer’s solution, or physiological salt buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

[0217] For oral administration, the pharmaceutical composition can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the pharmaceutical composition to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a patient. Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carbomethylcellulose; and / or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

[0218] Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone,carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

[0219] Pharmaceutical compositions which can be used orally, include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active ingredients may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for the chosen route of administration.

[0220] For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

[0221] For administration by nasal inhalation, the active ingredients for use according to some embodiments of the invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in a dispenser may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

[0222] The pharmaceutical composition described herein may be formulated for parenteral administration, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative. The compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and / or dispersing agents.

[0223] Pharmaceutical compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water-based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents whichincrease the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.

[0224] Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water-based solution, before use.

[0225] The pharmaceutical composition of some embodiments of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.

[0226] Pharmaceutical compositions suitable for use in context of some embodiments of the invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients effective to prevent, alleviate or ameliorate symptoms of a disorder (e.g., autoimmune disease) or prolong the survival of the subject being treated.

[0227] Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

[0228] For any preparation used in the methods of the invention, the therapeutically effective amount or dose can be estimated initially from in vitro and cell culture assays. For example, a dose can be formulated in animal models to achieve a desired concentration or titer. Such information can be used to more accurately determine useful doses in humans.

[0229] Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals. The data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 P-l).

[0230] Dosage amount and interval may be adjusted individually to provide TME levels of the active ingredient are sufficient to induce or suppress the biological effect (minimal effective concentration, MEC). The MEC will vary for each preparation, but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. Detection assays can be used to determine plasma concentrations.

[0231] According to specific embodiments, the composition is administered in a dose of up to 6xl013vg / kg.According to specific embodiments, the composition is administered in a dose of at least IxlO12vg / kg.

[0232] According to specific embodiments, the composition is administered in a dose ranging from about IxlO12vg / kg to about 6xl013vg / kg, for example from about IxlO12vg / kg to about 5xl012vg / kg, from about 5xl012vg / kg to about IxlO13vg / kg, from about IxlO13vg / kg to about 3xl013vg / kg, or from about 3xl013vg / kg to about 6xl013vg / kg, each possibility representing a separate embodiment of the invention.

[0233] According to specific embodiments, the composition is administered in a dose of IxlO13vg / kg.

[0234] Depending on the severity and responsiveness of the condition to be treated, dosing can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.

[0235] The amount of a composition to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.

[0236] Compositions of some embodiments of the invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition, as is further detailed above.

[0237] As used herein the term “about” refers to ± 10 %

[0238] The terms "comprises", "comprising", "includes", "including", “having” and their conjugates mean "including but not limited to".

[0239] The term “consisting of’ means “including and limited to”.

[0240] The term "consisting essentially of" means that the composition, method or structure may include additional ingredients, steps and / or parts, but only if the additional ingredients, stepsand / or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.

[0241] As used herein, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof.

[0242] Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

[0243] Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases “ranging / ranges between” a first indicate number and a second indicate number and “ranging / ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.

[0244] As used herein the term "method" refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.

[0245] When reference is made to particular sequence listings, such reference is to be understood to also encompass sequences that substantially correspond to its complementary sequence as including minor sequence variations, resulting from, e.g., sequencing errors, cloning errors, or other alterations resulting in base substitution, base deletion or base addition, provided that the frequency of such variations is less than 1 in 50 nucleotides, alternatively, less than 1 in 100 nucleotides, alternatively, less than 1 in 200 nucleotides, alternatively, less than 1 in 500 nucleotides, alternatively, less than 1 in 1000 nucleotides, alternatively, less than 1 in 5,000 nucleotides, alternatively, less than 1 in 10,000 nucleotides.

[0246] It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a singleembodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.

[0247] Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.

[0248] EXAMPLES

[0249] Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention in a non-limiting fashion.

[0250] Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques.

[0251] MATERIALS AND METHODS

[0252] Generation of the AAV vector - For the generation of plasmids encoding for murine CAR anti-CD19, the CAR coding plasmid MSGV-1D3-28Z All ITAMs intact from Steve Rosenberg was obtained from Addgene (#107226, SEQ ID NO: 13). The CAR sequence was modified using the insertion of Flag-tag and Myc-tag for CAR detection. Briefly, a leader sequence from Addgene (#107226) plasmid was replaced by a CD8a leader sequence, followed by a Myc-tag addition. In the construct, Rat VL-VH anti murine CD 19 scFV sequence is followed by a Flag-tag insertion using Notl-Nsil restriction endonucleases, with preserved restriction sites; and the CAR construct is followed by murine CD28 and CD3-zeta genes. This modified CAR sequence was cloned into the pscAAV-MCS vector (#VPK-410, scAAV) under the PGK promoter. The construct sequences and its components are provided in SEQ ID NOs: 1-11, and schematically shown in Figures 8A-B.

[0253] Ex Vivo Splenocyte Transduction - Primary murine T cells were isolated from spleens of C57BL / 6J01aHsd mice and prepared as single-cell suspensions. Red blood cells were lysed using RBC lysis buffer (BioLegend). Cells were cultured at a density of IxlO6cells / ml in RPMI 1640 supplemented with FBS, L-glutamine, antibiotics, P-mercaptoethanol, anti-mouse CD3 (clone 145-2C11, Biolegend, #100339, 0.08 pg / ml), anti-mouse CD28 (clone 37.51, Biolegend, #102115, 0.039 pg / ml) antibodies, and recombinant human IL-2 (Peprotech, #200-02,100 U / mL). After 48 hours of activation, cells were transduced with rAAV at a multiplicity of infection (MOI) of IxlO6. Cells (5xl05per well) were incubated with the virus for 25minutes at 37 °C, followed by expansion in fresh medium containing IL-2. Transduction efficiency was assessed 48-72 hours post-transduction.

[0254] Mouse splenocytes staining - Transduced splenocytes were collected and washed twice with PBS, and subsequently incubated for 20 minutes at room temperature in the dark with an antibody mix containing anti-mouse CD3 (APC, BioLegend, Cat#100236), anti-mouse CD20 (FITC, BioLegend, Cat#152112), anti-mouse CD19 (VioBlue, Miltenyi Biotec, Cat#130-lll-889), and anti-FLAG (PE, BioLegend, Cat#637310). Following staining, cells were washed with PBS, centrifuged, and resuspended for acquisition.

[0255] Animal Studies - All animal procedures were approved by the relevant institutional animal care and use committees and conducted in accordance with applicable guidelines.

[0256] Female MRL / lpr mice (The Jackson Laboratory, 11-13 weeks old) were used as a model for systemic lupus erythematosus (SLE) studies. Female C57BL / 6J01aHsd mice (8-12 weeks old) were used for healthy model experiments. Animals were maintained under standard housing conditions with controlled temperature, humidity, and light cycles. Mice were systemically injected via the tail vein with IxlO12vector genomes (vg) / mouse scAAV8-CAR anti-CD19 vectors or PBS control. Blood and urine samples were collected at various time points following injection for further evaluation (e.g., B cell depletion by flow cytometry and anti-DNA serology). In addition, representative animals were sacrificed at predetermined time points and their spleen length was evaluated using a ruler. At the end of the experiment (i.e., upon death of the animal), kidneys were harvested for pathology analysis.

[0257] ELISA - Plasma was prepared by centrifugation of blood at 2000g for 10 minutes and used to determine relative anti-DNA IgG antibodies. ELISA 96-well plates were coated with AffiniPure goat anti-mouse IgG(H+L) (#115-005-003, Jackson ImmunoResearch) in coating buffer [0.1 M NaHCOs (pH 9.6)] at 4 °C overnight. Coated plates were washed and incubated for 1 hour at room temperature in blocking buffer (1 % BSA in PBS with 0.02 % NaNs). For mouse IgG detection, 3-fold serial dilutions of the plasma were prepared in a blocking buffer and incubated at room temperature for 3 hours. The detection antibody (alkaline phosphatase-labeled goat anti-mouse IgG, at 1:1000 dilution) was added and incubated for 1 hour. Phosphatase detection substrate (Cat. no. S0942, Sigma- Aldrich) at 1 mg / ml was added for color development. Absorption in plates was read at 405 nm. The graph was built with the data from 1 : 225 plasma dilution.

[0258] Tissue preparation and pathology - Kidneys from MRL-lpr mice were flash-frozen in optimal cutting temperature (OCT) compound (Cat. no. 23-730-571, Fisher Biotec) and sectioned at 5 pm thickness using a cryotome. Kidneys were sectioned and analyzed forcellularity and morphology by hematoxylin and eosin (H&E) and Periodic acid-Schiff (PAS) stainings.

[0259] Histopathological evaluation - The H&E-stained slides were examined, described, and scored by the study Pathologist, using a semi-quantitative grading scale, of 5-point scale, for the severity of the histopathological changes (Schafer et al., Toxicologic Pathology 2018, 46:256-265):

[0260] Grade 0 - The tissue appears normal, without any changes at all.

[0261] Grade 1 - Minimal pathological findings.

[0262] Grade 2 - Mild pathological findings.

[0263] Grade 3 - Moderate pathological findings.

[0264] Grade 4 - Severe pathological findings.

[0265] A semi-quantitative analysis of the immunohistochemical reaction for PAS was performed using a scoring scale as follows:

[0266] Grade 0= no positive reaction at all

[0267] Grade 1= Only a few membranes are positive

[0268] Grade 2= Very mild positive reaction (5-15 per a X20 field)

[0269] Grade 3= Mild positive reaction (15-25 per a X20 field)

[0270] Grade 4= Moderate positive reaction (25-50 per a X20 field)

[0271] Grade 5= Marked positive reaction (>50 per a X20 field)

[0272] Flow cytometry - Flow cytometric analysis was performed on a Cytek Aurora CS spectral flow cytometer (Cytek Biosciences), Attune NxT (Life Technologies) or CytoFLEX (Beckman Coulter). Fluorescence emission spectra were unmixed in real-time using the instrument’s onboard full spectrum unmixing algorithms utilizing single- stained reference controls (antibody-capture beads or cells stained with each fluorophore). Data were analyzed using FlowJo or Kaluza Analysis 2.1 (Beckman Coulter). Cells were extracted from harvested tissues and washed twice in IxPBS and then resuspended in cell staining buffer (BioLegend). Whole blood samples were lysed using Red Blood Cell Lysis Buffer (Sigma-Aldrich, Cat # R7757) according to manufactures guidelines. Cell pellet was resuspended in 100 pL of 1 % BSA buffer, added with 2 pL (for lx 106cells) of anti-mouse TruStain FcX (catalog# 101319) and incubated for 15 minutes at 4 °C. Conjugated antibodies directed against relevant markers were added directly to the cell suspension, as indicated in the legend. The following antibodies were used: anti-CD3 (PerCp 5.5, Tonbo Bioscience, CAT#65-0031), anti-CD8 (APCH7, BD Bioscience, CAT#560182), anti-CD19 (PE CF594, BD Horizon: Cat#552291), anti-CD20 (BV605, Biolegend: Cat#150435), anti-CD44 (APC-Cy7, BD Pharmingen: Cat#560568), anti-CD62L (BV605, BD Horizon: Cat#563252). Incubation was performed in the dark for 20-30 minutes at 4 °C. Following incubation, the cells were washed twice in IxPBS and resuspended in IxPBS for data acquisition. Alternatively, the cells were washed with 1 mL of PBS without Ca2+or Mg2and cells were resuspended in viability dye Zombie Aqua (BioLegend, Cat#423101 / 77143) 1:600 and incubated for 30 minutes in dark at 4 °C. Samples were washed, resuspended in 1% BSA and filtered through a 40 pm strainer.

[0273] Healthy C57B\6 blood staining - Peripheral blood was collected from mice via submandibular bleeding into microcentrifuge tubes containing Heparin (Merck, 5 kU / mL). Red blood cells were lysed using lx RBC lysis buffer (Biolegend), followed by two PBS washes. The cell pellet was resuspended in PBS. Cells were incubated for 20 minutes at room temperature in the dark with an antibody mix containing anti-mouse CD45.2 (BV421, BioLegend, Cat#109831) and anti-mouse CD3 (FITC, BioLegend, Cat#100204), in combination with either a B cell panel of anti-mouse CD19 (APC, Miltenyi Biotec, Cat#130-l 11-884) and anti-mouse CD20 (PE, BioLegend, Cat#150410) or a CAR detection panel of anti-G4S linker (APC, Cell Signaling, Cat#69782L) and anti-FLAG (PE, BioLegend, Cat#637310). Following staining, cells were washed with PBS, centrifuged, and resuspended for flow cytometry acquisition as described above.

[0274] AAV biodistribution - For evaluating AAV copy number biodistribution, representative MRL-lpr mice were sacrificed 7 days following injection and liver, spleen, thymus, lung, heart, kidney and bone marrow samples were harvested. Following, DNA was extracted from the harvested tissue samples using Quick-DNA Miniprep Kit (Zymo Research) with RNAse treatment on-column. Extracted DNA from tissue samples was further evaluated by qPCR analysis for the presence of AAV genomes and in particular the CAR construct. Each sample was analyzed for both internal control (IgGl heavy chain) and the AAV (CAR anti-CD19) presence. For quantification of AAV copy number per haploid genome, a standard curve was used. Standards were prepared from the plasmids encoding for the internal control (IgGl heavy chain) or the AAV plasmid used in the study. The list of primers used for AAV, and internal control reactions is provided in Table 1 hereinbelow. Standard curve plasmids were serially diluted 8 times. Data collection and analysis were performed on a StepOnePlus qPCR System (Applied Biosystems) using SYBRGreen (PCR Biosystems).Table 1: list of primers

[0275] SEQ ID NO: 14 AAV BioF2 5’- CCATGGCCTTACCAGTGACCG

[0276] SEQ ID NO: 15 AAV BioR3 5’- ATGTCACGCGTTGGGAGGT

[0277] SEQ ID NO: 16 ddPCR mh69 F 5’- CTTGTAGCTGTGGTTTGAAGAAG

[0278] SEQ ID NO: 17 ddPCR mh69 R 5’- TCGGCTGAATCCTCAACTTATT

[0279]

[0280] EXAMPLE 1

[0281] AN AAV VECTOR DELIVERING A CAR GENE PAYLOAD IN-VIVO IN AN SLE MOUSE MODEL

[0282] The present inventors conceptualized a gene therapy approach using an AAV vector encoding a CAR cassette targeting a B cell- specific antigen, for the treatment of B cell-mediated autoimmune diseases such as systemic lupus erythematosus (SLE). To this end, they generated an AAV vector, referred to herein as “scAAV8-CAR anti-CD19”, containing a polynucleotide encoding an anti-mouse CD 19 CAR payload, driven by a PGK promoter and designed for transient expression in transduced cells without genomic integration, as the construct lacks targeting sequences, integration moieties, or associated targeted nucleases (see Figures 8A-B). In the generated CAR, the ScFv was coupled with a mouse CD3(^ signaling domain and a mouse CD28 co- stimulatory domain to ensure robust T cell activation and proliferation.

[0283] scAAV8-mediated CAR transduction and functional activity was evaluated ex-vivo in activated murine CD3+splenocytes. CAR expression was analyzed 48 hours post-transduction, revealing that approximately 10 % of T cells expressed the transgene (Figures 9A-B). Functional assessment demonstrated that scAAV8-CAR-transduced T cells mediated depletion of endogenous B cells compared with non-transduced controls (Figures 9C-D).

[0284] Next, to assess the activity of the vector was evaluated in-vivo. To this end, 10-week-old C57BL / 6 mice were systemically injected with a single intravenous dose of 1 x 1012vg / mouse scAAV8-CAR anti-CD19 vectors or HBSS control (Figure 10A). It was hypothesized that CAR- T cells generated in-vivo would undergo antigen-dependent activation and mediate targeted cytotoxicity against B cells. Flow cytometry analysis of peripheral blood 7 days post-injection revealed that CD19+B cells constituted 0.8 % of circulating lymphocytes in the vector-treated mice, compared with 52 % in the controls (Figures 10B-C). By day 21, vector-treated mice exhibited complete B cell aplasia, which persisted for up to 4 weeks, followed by gradual recovery of CD19+cells, consistent with transient CAR expression and in-vivo CAR-T cell activity. Similar kinetics was found when staining for the CD20 B cell marker (Figures 10D-E), ruling out CD19 internalization as an account for the apparent aplasia. Notably, scAAV8-CARanti-CD19 administration was associated with a significant increase in T cell frequencies (Figures 10F-G). Collectively, these findings demonstrate that in-vivo generated CAR-T cells can induce robust and transient B cell depletion, supporting further evaluation in an autoimmune disease murine model, focusing on systemic lupus erythematosus.

[0285] Encouraged by the success of the scAAV8-CAR in depleting endogenous B cells in healthy C57BL6 mice, the study was expanded to evaluate the effect of the vector in the MRL / lpr immunocompetent lupus mouse model, a well-established model of SLE.

[0286] Analyzing the distribution of the in-vivo injected vectors 7 days following injection revealed detectable levels of the scAAV8-CAR vector in the liver, spleen and heart of treated mice (Figure 7). Notably, the intravenous administration of the vector primarily transduced liver cells, an organ notorious for accumulating high levels of rAAV8 vector particles.

[0287] Following, the therapeutic effect of the vector was evaluated in the MRL / lpr immunocompetent lupus mouse model. To this end, 11 weeks old MRL-lpr female mice (Figure 1A) or 13 weeks old MRL-lpr female mice (Figure 11A) were systemically injected with lxl012vg / mouse scAAV8-CAR anti-CD19 vectors or PBS control in a single dose. In both experimental set-ups, the vector-treated mice exhibited profound but transient B cell aplasia in peripheral blood, bone marrow and spleen within weeks, indicating effective CAR-T cell-mediated B cell depletion (Figures 1B-C, 2-3, 11B-C and 11F-G). This B cell aplasia correlated with a significant reduction in anti-double-stranded DNA (anti-dsDNA) autoantibodies, a hallmark of lupus pathogenesis (Figures ID and 11L).

[0288] In contrast, analysis of the blood and bone marrow revealed significant increases in T cell counts in scAAV8-CAR treated mice, compared to the PBS injected controls (Figures 1B-C and 11H-I), especially CD8+ T cells (Figures 11D-E). Further phenotypic analysis of T cells, indicated a significant increase in effector (CD44hlghCD62Llow) T cells accompanied by a reduction in central memory (CD44hlghCD62Lhlgh) and naive (CD44lowCD62Lhlgh) T cells (Figures 4 and 11J-K).

[0289] Additionally, spleen size, typically enlarged in MRL / LPR mice due to lymphoproliferation, was markedly reduced in treated animals (Figure 5). Further, the effects of B cell depletion induced by scAAV8-CAR on the pathogenesis of lupus in the kidneys was evaluated by analyzing kidney sections for cellularity and morphology by H&E and PAS staining. All H&E-stained evaluated kidneys had demonstrated mild to severe periarterial infiltration of a homogenous population of cells, mainly lymphocytes and macrophages. Affected kidneys included mild to severe protein losing nephropathy with the accumulation of protein depositions in the proximal and distal tubule, glomeruli and in the collection ducts.Periglomerular inflammatory response, as well as loss of glomerular structure and a notable thickening of glomeruli basement and Bowman’s cavity membranes in several samples (as indicated by PAS staining). The individual scoring per sample is listed in Table 2 hereinbelow. Importantly, the histopathological score confirmed that all 4 control mice showed severe pathological findings, whereas, among the AAV-treated group, 4 out of 5 mice demonstrated less severe manifestation of the disease (Figures 1E-F). Taken together, these results indicate substantial amelioration of lupus-associated glomerulonephritis and immune complex deposition, indicating a direct therapeutic impact on end-organ damage.

[0290] Furthermore, as an indicator of disease progression, high-grade proteinuria (>1 mg / ml) was assessed 10 weeks after experimental initiation (Figure 11M). At the start of the experiment, none of the animals had high-grade proteinuria, while at 10 weeks high-grade proteinuria occurred in 4 / 7 PBS mice (57.1 %) and 2 / 12 scAAV8-CAR anti-CD19 mice (16.7 %).

[0291] Most strikingly, while 4 out of 5 untreated control mice succumbed to lupus by day 180 post-birth, CAR- AAV-treated mice demonstrated significantly prolonged survival (Figure 6), highlighting the therapeutic potential of this approach.

[0292] Taken together, these results indicate the successful generation of CAR-T cells in-vivo in an SLE murine model, leading to a transient depletion of CD19+B cells, suppressed production of autoantibodies and reduced manifestation of the disease in the kidneys and most notably, prolonged survival of the treated animals.

[0293] Table 2: A semi-quantitative analysis of the histopathological findings, using the scoring scale described in the Materials and Methods section hereinabove

[0294] Sample No H&E PAS

[0295] PBS 2280 4 4

[0296] 2285 4 5

[0297] 2282 3 1

[0298] 2284 3 2

[0299] scAAV-CAR 2278 2 1

[0300] 2287 2 0

[0301] 2291 1 1

[0302] 2290 3 2

[0303] 2283 1 1

[0304]

[0305] Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.

[0306] All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting. In addition, any priority document(s) of this application is / are hereby incorporated herein by reference in its / their entirety.

[0307] Table 3: list of sequences

[0308] SEQ ID Construct AAAGCTTCCCGGGGGGATCTGGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCC NO: 1 pNG106: GGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCG mCAR anti- AGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCTGGAGGGGTGGAGTCG CD19 TGACCTAGCACCTTCTACTCCTCCCCTAGTCAGGAAGTTCCCCCCCGCCCCGCAGCTCGCGT CGTGCAGGACGTGACAAATGGAAGTAGCACGTCTCACTAGTCTCGTGCAGATGGACAGCA CCG CTG AG CAATG G AAG CG G GTAG G CCTTTG GGGCAGCGG CC AATAG C AG CTTTG CTCCT TCGCI 1 I CI GGGCTCAGAGGCTGGGAAGGGGTGGGTCCGGGGGCGGGCTCAGGGGCGGG CTCAGGGGCGGGGCGGGCGCCCGAAGGTCCTCCGGAGGCCCGGCATTCTGCACGCTTCAA AAG CG CACGTCTG CCG CG CTGTTCTCCTCTTCCTC ATCTCCG G G CCTTTCG AATTCTCCTCTA GACCCTGCAGGTTAATTAAGCCGCCATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTG GCCTTGCTGCTCCACGCCGCCAGGCCGACGCGAGAGCAAAAACTTATCTCTGAAGAGGACC TCCCAACGCGTGACATCCAGATGACCCAGAGCCCTGCCAGCCTGTCTACCAGCCTGGGCGA GACAGTGACCATCCAGTGTCAGGCCAGCGAGGACATCTACTCTGGCCTGGCTTGGTATCAG CAGAAGCCCGGCAAGAGCCCTCAGCTGCTGATCTACGGCGCCAGCGACCTGCAGGACGGC GTGCCTAGCAGATTCAGCGGCAGCGGCTCCGGAACCCAGTACAGCCTGAAGATCACCAGC ATGCAGACCGAGGACGAGGGCGTGTACTTCTGCCAGCAAGGCCTGACCTACCCTAGAACC TTCGGAGGAGGCACCAAGCTGGAACTGAAGGGCGGAGGCGGAAGTGGAGGCGGAGGAT CTGGCGGCGGAGG CTCTG AAGTG CAG CTG CAG CAGTCTG G CG CTG AACTG GTCCG G CCTG G CACTAG CGTG AAG CTGTCCTG CAAG GTGTCCG G CG ACACCATCACCTTCTACTAC ATG CA CTTCGTGAAGCAGAGGCCAGGACAGGGCCTGGAATGGATCGGCAGAATCGACCCTGAGG ACGAGAGCACCAAGTACAGCGAGAAGTTCAAGAACAAGGCCACCCTGACCGCCGACACCA GCAGCAACACCGCCTACCTGAAGCTGTCTAGCCTGACCTCCGAGGACACCGCCACCTACTT TTG CATCTACG G CG G CTACTACTTCG ACTACTG GGGCCAGGG CGTG ATG GTCACCGTGTCC

[0309]

[0310] AGCAGCGGCCGCGACTACAAAGACGATGACGACAAGATGCATATCGAGTTCATGTATCCTC CTCCTTATCTGGATAACGAAAGAAGCAACGGCACAATTATTCACATCAAGGAAAAACACCT GTG CCAC ACCCAATCCAG CCCTAAACTGTTCTG G G CCCTG GTCGTG GTG G CTG G CGTCCTG TTCTGCTACGGCCTGCTCGTGACCGTGGCCCTGTGTGTGATCTGGACCAATTCCAGAAGGA ATAGGGGCGGCCAGTCCGATTACATGAATATGACCCCTAGGAGGCCTGGCCTGACTAGAA AACCCTACCAGCCTTACGCCCCTGCAAGAGACTTTGCTGCCTATCGGCCCAGAGCTAAATTC AGCAGGAGCGCTGAAACCGCTGCCAACCTGCAGGATCCTAATCAGCTGTATAACGAGCTG AACCTCGGCAGAAGGGAGGAGTACGATGTGCTCGAGAAGAAGAGAGCTAGAGACCCTGA GATGGGAGGCAAACAGCAGAGAAGAAGGAATCCTCAGGAGGGGGTGTACAACGCTCTCC AGAAAGATAAGATGGCTGAGGCATATTCCGAAATCGGAACCAAAGGCGAGAGAAGAAGG GGAAAAGGCCATGACGGACTGTACCAGGGACTCAGCACCGCCACAAAGGATACCTACGAC GCTCTGCATATGCAGACCCTCGCCCCTAGATAGCCTCTAGACCATCGATGCGGCCGCTAGG CCTCACCTGCGATCTCGATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACC ATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCA GGGGGAGGTGTGGGAGGTTTTTTAAACTAGTCCACTCCCTCTCTGCGCGCTCGCTCGCTCA CTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGA GCGAGCGAGCGCGCAGAGAGGGACAGATCCGGGCCCGCATGCGTCGACAATTCACTGGC CGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAG CACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCA ACAGTTGCGCAGCCTGAATGGCGAATGGCGCCTGATGCGGTATTTTCTCCTTACGCATCTG TGCGGTATTTCACACCGCATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTT AAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCG GCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCAC CGTCATCACCGAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTAI 1 1 1 I ATAGGTTAA TGTCATG ATAATAATG GTTTCTTAG ACGTCAG GTG GCACTTTTCGG GG AAATGTG CGCG G A ACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCC TGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCG CCCTTATTCCC I I l l i I GCGGCAI 1 1 I GCCI I CCI G I 1 1 1 1 GCTCACCCAGAAACGCTGGTGA AAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCA ACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTT AAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTC GCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTT ACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACT GCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACA ACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATAC CAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATT AACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGAT AAAGTTG C AG G ACCACTTCTG CG CTCG G CCCTTCCG G CTG G CTG GTTTATTG CTG ATAAATC TGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCC

[0311]

[0312] CTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGA CAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACT CATATATACTTTAGATTGATTTAAAACTTCA 1 1 1 1 1 AATTTAAAAGGATCTAGGTGAAGATCC 1 1 1 1 1 GATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACC CCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTG CAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTC

[0313] I l l i 1 CCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAG CCGTAGTTAGG CCACCACTTCAAG AACTCTGTAG CACCG CCTACATACCTCGCTCTG CTAAT CCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGA CGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCC CAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAG CGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAA CAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCG GGTTTCGCCACCTCTGACTTGAGCGTCGAI 1 1 1 1 GTGATGCTCGTCAGGGGGGCGGAGCCT ATGGAAAAACGCCAGCAACGCGGCCI 1 1 1 1 ACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTC ACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAG CTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCG GAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCT GGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTT AG CTCACTCATTAG G CACCCCAG G CTTTACACTTTATG CTTCCG G CTCGTATGTTGTGTG G A ATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCT CGAGATCTAG SEQ ID PGK Promoter ACCTTCTACTCCTCCCCTAGTCAGGAAGTTCCCCCCCGCCCCGCAGCTCGCGTCGTG NO: 2 CAGGACGTGACAAATGGAAGTAGCACGTCTCACTAGTCTCGTGCAGATGGACAGC ACCGCTGAGCAATGGAAGCGGGTAGGCCTTTGGGGCAGCGGCCAATAGCAGCTT TGCTCCTTCGCTTTCTGGGCTCAGAGGCTGGGAAGGGGTGGGTCCGGGGGCGGG CTCAGGGGCGGGCTCAGGGGCGGGGCGGGCGCCCG SEQ ID CD8a leader ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGC NO: 3 sequence CAGGCCG

[0314] SEQ ID C-myc tag GAGCAAAAACTTATCTCTGAAGAGGACCTC

[0315] NO: 4

[0316]

[0317] SEQ ID anti-CD19 GACATCCAGATGACCCAGAGCCCTGCCAGCCTGTCTACCAGCCTGGGCGAGACAG NO: 5 ScFv TGACCATCCAGTGTCAGGCCAGCGAGGACATCTACTCTGGCCTGGCTTGGTATCA GCAGAAGCCCGGCAAGAGCCCTCAGCTGCTGATCTACGGCGCCAGCGACCTGCA GGACGGCGTGCCTAGCAGATTCAGCGGCAGCGGCTCCGGAACCCAGTACAGCCT GAAGATCACCAGCATGCAGACCGAGGACGAGGGCGTGTACTTCTGCCAGCAAGG CCTGACCTACCCTAGAACCTTCGGAGGAGGCACCAAGCTGGAACTGAAGGGCGG AGGCGGAAGTGGAGGCGGAGGATCTGGCGGCGGAGGCTCTGAAGTGCAGCTGC AGCAGTCTGGCGCTGAACTGGTCCGGCCTGGCACTAGCGTGAAGCTGTCCTGCAA GGTGTCCGGCGACACCATCACCTTCTACTACATGCACTTCGTGAAGCAGAGGCCA GGACAGGGCCTGGAATGGATCGGCAGAATCGACCCTGAGGACGAGAGCACCAA GTACAGCGAGAAGTTCAAGAACAAGGCCACCCTGACCGCCGACACCAGCAGCAA CACCGCCTACCTGAAGCTGTCTAGCCTGACCTCCGAGGACACCGCCACCTACI 1 1 1 GCATCTACGGCGGCTACTACTTCGACTACTGGGGCCAGGGCGTGATGGTCACCGT GTCCAGC SEQ ID flag-tag GACTACAAAGACGATGACGACAAG

[0318] NO: 6

[0319] SEQ ID Mouse CD28 ATCGAGTTCATGTATCCTCCTCCTTATCTGGATAACGAAAGAAGCAACGGCACAAT NO: 7 domain TATTCACATCAAGGAAAAACACCTGTGCCACACCCAATCCAGCCCTAAACTGTTCT GGGCCCTGGTCGTGGTGGCTGGCGTCCTGTTCTGCTACGGCCTGCTCGTGACCGT GGCCCTGTGTGTGATCTGGACCAATTCCAGAAGGAATAGGGGCGGCCAGTCCGAT TACATGAATATGACCCCTAGGAGGCCTGGCCTGACTAGAAAACCCTACCAGCCTTA CGCCCCTGCAAGAGACTTTGCTGCCTATCGGCCC SEQ ID Mouse CD3 AGAGCTAAATTCAGCAGGAGCGCTGAAACCGCTGCCAACCTGCAGGATCCTAATC NO: 8 zeta domain AGCTGTATAACGAGCTGAACCTCGGCAGAAGGGAGGAGTACGATGTGCTCGAGA AGAAGAGAGCTAGAGACCCTGAGATGGGAGGCAAACAGCAGAGAAGAAGGAAT CCTCAGGAGGGGGTGTACAACGCTCTCCAGAAAGATAAGATGGCTGAGGCATATT CCGAAATCGGAACCAAAGGCGAGAGAAGAAGGGGAAAAGGCCATGACGGACTG TACCAGGGACTCAGCACCGCCACAAAGGATACCTACGACGCTCTGCATATGCAGA CCCTCGCCCCTAGATAG SEQ ID SV40-polyA ATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTG NO: 9 CAATAAACAAGTTAACAACAACAATTGCATTCAI 1 1 1 ATGTTTCAGGTTCAGGGGG AGGTGTGGGAGG 1 1 1 1 1 1 AAA

[0320] SEQ ID AAV ITR CCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCC NO: 10 CGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAG

[0321] GGA

[0322]

[0323] SEQ ID AAV ITR CCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCC NO: 11 CGACGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAG GGA SEQ ID Protein MALPVTALLLPLALLLHAARPTREQKUSEEDLPTRDIQMTQSPASLSTSLGETVTIQCQ NO: 12 sequence of ASEDIYSGLAWYQQKPGKSPQLLIYGASDLQDGVPSRFSGSGSGTQYSLKITSMQTED mCAR anti- EGVYFCQQGLTYPRTFGGGTKLELKGGGGSGGGGSGGGGSEVQLQQSGAELVRPGT CD19

[0324] SVKLSCKVSGDTITFYYMHFVKQRPGQGLEWIGRIDPEDESTKYSEKFKNKATLTADTS SNTAYLKLSSLTSEDTATYFCIYGGYYFDYWGQGVMVTVSSSGRDYKDDDDKMHIEF MYPPPYLDNERSNGTIIHIKEKHLCHTQSSPKLFWALVVVAGVLFCYGLLVTVALCVIW TNSRRNRGGQSDYMNMTPRRPGLTRKPYQPYAPARDFAAYRPRAKFSRSAETAANL QDPNQLYNELNLGRREEYDVLEKKRARDPEMGGKQQRRRNPQEGVYNALQKDKM AEAYSEIGTKGERRRGKGHDLGYQGLSTATKDTYDALHMQTLAPR*

[0325] mCAR anti- ATGGGTGTCCCTACCCAGCTCCTGGGACTGCTCCTGCTGTGGATCACCGACGCCAT CD19 CTGCGACATCCAGATGACCCAGAGCCCTGCCAGCCTGTCTACCAGCCTGGGCGAG (Addgene ACAGTGACCATCCAGTGTCAGGCCAGCGAGGACATCTACTCTGGCCTGGCTTGGT #107226,

[0326] ATCAGCAGAAGCCCGGCAAGAGCCCTCAGCTGCTGATCTACGGCGCCAGCGACCT

[0327] Steven

[0328] GCAGGACGGCGTGCCTAGCAGATTCAGCGGCAGCGGCTCCGGAACCCAGTACAG

[0329] Rosenberg,

[0330] CCTGAAGATCACCAGCATGCAGACCGAGGACGAGGGCGTGTACTTCTGCCAGCAA MSGV-1D3- GGCCTGACCTACCCTAGAACCTTCGGAGGAGGCACCAAGCTGGAACTGAAGGGC

[0331] 28Z AII ITAMs

[0332] intact) GGAGGCGGAAGTGGAGGCGGAGGATCTGGCGGCGGAGGCTCTGAAGTGCAGCT GCAGCAGTCTGGCGCTGAACTGGTCCGGCCTGGCACTAGCGTGAAGCTGTCCTGC AAGGTGTCCGGCGACACCATCACCTTCTACTACATGCACTTCGTGAAGCAGAGGC CAGGACAGGGCCTGGAATGGATCGGCAGAATCGACCCTGAGGACGAGAGCACCA AGTACAGCGAGAAGTTCAAGAACAAGGCCACCCTGACCGCCGACACCAGCAGCA ACACCGCCTACCTGAAGCTGTCTAGCCTGACCTCCGAGGACACCGCCACCTACTTT TGCATCTACGGCGGCTACTACTTCGACTACTGGGGCCAGGGCGTGATGGTCACCG TGTCCAGCATCGAGTTCATGTACCCCCCTCCCTACCTGGACAACGAGAGAAGCAAC GGCACCATCATCCACATCAAAGAAAAGCACCTGTGCCACACCCAGAGCAGCCCCA AGCTGTTCTGGGCCCTGGTGGTGGTGGCCGGCGTGCTGTTCTGTTACGGCCTGCT GGTCACAGTGGCCCTGTGCGTGATCTGGACCAACAGCAGAAGAAACAGAGGCGG CCAGAGCGACTACATGAACATGACCCCCAGAAGGCCAGGCCTGACCAGAAAGCCC TACCAGCCCTACGCCCCTGCCAGAGACTTCGCCGCCTACAGACCCAGAGCCAAGTT CAGCAGATCCGCCGAGACAGCCGCCAACCTGCAGGATCCCAACCAGCTGTACAAC GAGCTGAACCTGGGCAGACGGGAGGAATACGACGTGCTGGAAAAGAAGAGAGC CAGGGACCCCGAGATGGGCGGCAAGCAGCAGAGAAGAAGAAACCCTCAGGAAG

[0333]

[0334] GCGTCTACAACGCCCTGCAGAAAGACAAGATGGCCGAGGCCTACAGCGAGATCG GCACCAAGGGCGAGAGAAGAAGGGGCAAGGGCCACGATGGCCTGTACCAGGGC CTGTCCACCGCCACCAAGGACACCTACGACGCCCTGCACATGCAGACCCTGGCCCC CAGATGA

[0335]

Claims

WHAT IS CLAIMED IS:

1. A composition comprising an adeno-associated virus (AAV) vector comprising a nucleic acid sequence encoding a heterologous immune cell activating transmembrane protein comprising an extracellular binding domain that binds an antigen expressed by a target immune cell; and a cis-acting regulatory element for directing expression of said nucleic acid sequence, wherein said composition is devoid of a genome integration moiety such that said nucleic acid sequence is transiently expressed in a cell infected with said composition.

2. The composition of claim 1, wherein said immune cell activating transmembrane protein is a T cell transmembrane protein.

3. The composition of any one of claims 1-2, wherein said immune cell transmembrane protein is selected from the group consisting of a chimeric antigen receptor (CAR), a chimeric autoantibody receptor (CAAR) and a T cell receptor (TCR).

4. The composition of any one of claims 1-2, wherein said immune cell transmembrane protein is a chimeric antigen receptor (CAR).

5. The composition of any one of claims 1-4, wherein said target immune cell is a B cell.

6. The composition of claim 5, wherein said antigen is selected from the group consisting of CD 19, CD20 and IgE receptor.

7. The composition of claim 5, wherein said antigen is CD 19.

8. The composition of any one of claims 1-7, wherein said immune cell transmembrane protein comprises an intracellular domain of CD3zeta and an intracellular domain of a costimulatory molecule.

9. The composition of claim 8, wherein said costimulatory molecule is CD28.

10. The composition of any one of claims 1-9, wherein said AAV vector comprises a T cell targeting moiety.

11. The composition of claim 10, wherein said T cell targeting moiety is selected from the group consisting of a Designed Ankyrin Repeat Protein (DARPin), an antibody, a ligand and a peptide mimetic.

12. The composition of any one of claims 1-11, wherein said cis-acting regulatory element comprises a promoter.

13. The composition of claim 12, wherein said promoter is a constitutive promoter.

14. The composition of any one of claims 12-13, wherein said promoter is selected from the group consisting of PGK, EFla and MSCV.

15. The composition of any one of claims 12-13, wherein said promoter is a T cell specific promoter.

16. The composition of any one of claims 1-15, wherein said nucleic acid sequence further comprises a polyadenylation signal.

17. The composition of any one of claims 1-16, wherein said vector further encodes an additional heterologous expression product selected from the group consisting of a therapeutic agent, a detectable agent and a safety switch.

18. A method of treating an autoimmune disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the composition of any one of claims 1-17, thereby treating the autoimmune disease in the subject.

19. The composition of any one of claims 1-17 for use in treating an autoimmune disease in a subject in need thereof.

20. The method of claim 18 or the composition for use of claim 19, wherein said autoimmune disease is selected from the group consisting of systemic lupus erythematosus(SLE), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Myasthenia Gravis (MG), Multiple Sclerosis (MS), Sjogren’s Syndrome (SjD) and Rheumatoid Arthritis (RA).

21. The method of claim 18 or the composition for use of claim 19, wherein said autoimmune disease is systemic lupus erythematosus (SLE).

22. The method of composition for use of any one of claims 18-21, wherein said composition is administered intravenously.